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Summary
Summary
Nonnatural amino acid incorporation is a valuable method for introducing novel chemical 
functional groups into proteins. For this method, an orthogonal aminoacyl-tRNA synthetase (AARS) and 
a cognate tRNA that suppress an encoded stop codon are introduced into the cell (these components are 
required to be orthogonal). Nonnatural amino acids (NAAs) are usually incorporated efficiently by using 
Methanocaldococcus jannaschii tyrosyl-AARS/tyrosyl-tRNA pair {Mj TyrRS/A// tRNATyr) in 
Escherichia coli. High translation fidelity of a synthetase is achieved by site-directed mutagenesis of the 
competent active site residues. The active site of the mutant Mj TyrRS displays two crucial mutations of 
residues that interact with the tyrosine hydroxyl group (-OH). We demonstrated that the fidelity of the 
synthetase would be affected if only one of these residues is restored and does not undergo mutagenesis. 
We found a similar situation in the case of tryptophanyl-AARS (TrpRS) from Bacillus subtilis. TrpRSs 
are structurally similar to TyrRSs, but there is one crucial residue of the substrate specificity. We 
uncovered that a NAA system developed to incorporate 5-hydroxytryptophan (5-OH Trp) in mammalian 
cells does not contain this crucial residue mutation in the TrpRS active site. Even though this mutant 
TrpRS was designated as a high fidelity enzyme, our results challenge this conclusion.
Expanded genetic codes have a similar capacity to impact science as has standard mutagenesis. 
Only the full impact of the method will be achieved if the technology functions in all cell types. 
Therefore, our reinvestigation of the first report of expanded genetic code in mammalian system is 
critical to ensuring that the field is on the optimum path to realising the full potential of the method.
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Introduction
Introduction
The expanded genetic code field is based upon well-known textbook ideas such as site-directed 
mutagenesis, translation, enzyme function and kinetics, structure function. In order to introduce our 
work, a partial review of some concepts is provided here.
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Introduction
1. The Amino Acids of Proteins
Amino acids (AAs) are the building blocks of proteins.1 There are only 20 common amino acids 
assigned by 61 coding triplet combinations plus 3 stop codons. All known organisms share these 20 
common amino acids and although their chemical properties are quite limited they are responsible for
protein diversity and their distinct properties. Two other, rather rare natural amino acids, selenocysteine
(Sec)2 and pyrollysine (Pyl)3 were discovered later.4
In the structure of a single amino acid, there is a variable side chain, which is typically classified as 
R. In each amino acid, there is a central tetrahedral Ca covalently joined to the amino (-NH2) and the 
carboxyl (-COOH) group. Ca also links to a hydrogen atom. Depending on pH, an amino acid gains a 
charge. At pH 7, the carboxyl group exists as -COO' and the amino group as -NH 3+ so the overall 
molecule is neutral and it is called a zwitterion (Figure 1). Amino and carboxyl groups can react together 
after losing a water molecule to form a covalent amide bond (peptide bond). Polymerization of amino 
acids results in peptide chain assembling. In this manner, a new polypeptide or protein is formed.1
H H
H  - \ l +-------
/
H R
Figure 1: Amino acid general 
structure. -NH3+ and -COO' 
are linked to the C„ that is also 
substituted with a hydrogen 
atom and a R-group.
been made to study enzymes, their structures, functions and their involvement in
For each enzyme’s unique features, there has always been an attempt to be able to
16
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biological processes.5
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manipulate with their structure and thereby generate some new properties. As mentioned, there are only 
20 common amino acids and their chemical properties do not vary widely. Despite this inherent 
limitation, life has flourished with a diverse array of life forms. To help unlock the secrets of life, 
scientists developed methods to mutate one amino acid into one of the other 19 common ones and in this 
way, they have shone light on a number of life’s processes.
As early as 1962, researchers became interested in mutating a common amino acid into a 
nonnatural one.6 Since then, scientists have investigated a number of ways to introduce nonnatural amino 
acids into proteins. The desire to do so stems from the fact that nonatural amino acids (NAAs) are unique 
and differ from the classical 20 amino acids by their side group modification.7 For instance, some of 
these amino acids are metal chelators, photoaffinity labels or have distinctive spectroscopic properties. 
NAAs that we do not normally find in living organisms have been used as a target for incorporation into 
proteins. In this manner, protein properties (acidity, nucleophilicity, hydrogen-bonding potential, etc.)
can be enhanced. Proteins containing a NAA have been used for biophysical, chemical and structural
8 10studies. ' The development of the NAA incorporation method is the main motivation for this work.
In the cell, proteins are synthesized during translation.11 In this process, a messenger RNA (mRNA) 
molecule is used as a template, in which an order of nucleotides gives the information about how a new 
amino acid chain will assemble. There are specific enzymes required during translation. There would be 
no chance for the cell to survive if these catalysts were not involved in translation.12 Aminoacyl-tRNA 
synthetase (AARS) is an enzyme that catalyzes the first steps of protein biosynthesis.13 This enzyme is 
the focus of our work therefore, its function and structure will be described more in the next chapter.
17
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2. Study of Aminoacyl-tRNA synthetases (AARSs)
Central to this work are a class of enzymes called AARSs. They are key components in translation 
and contribute to the fidelity of the genetic code by a number of well studied mechanisms. Our 
motivation for studying them stems from our desire to incorporate nonnatural amino acids in vivo and, as 
such, having an intimate understanding of these key players in translation14 is essential to understanding 
how these enzymes can be best used in expanded genetic codes.
To begin with, AARSs perform key reactions. In these reactions, the AA, adenosine-5’-triphoshate 
(ATP) and transfer RNA (tRNA) are engaged. In a summary o f this process, AARS is involved in an 
ester bond formation between AA and tRNA terminal hydroxyl group of adenosine (either 2'-hydroxyl, 
2'OH or 3'-hydroxyl, 3'OH group15).13
AA + ATP + tRNA -► AA-tRNA + AMP + PP,
The products of this reaction are the AA bound to tRNA (AA-tRNA), adenosine-5’-monophosphate 
(AMP) and pyrophosphate (PPi). Without the formation of AA-tRNA (Figure 2), AA would not be 
transfered to the ribosome and the peptide chain would not form. There are at least two known 
mechanisms of aminoacylation in the cell. In a direct acylation there are 20 different AA-tRNA 
complexes that are products of direct charging by one of 20 different AARS’s. Thus, one AARS uses one 
amino acid of the genetic code.11, 16 An indirect pathway of acylation (tRNA-dependent amino acid 
modification) is the incorporation of Sec (21st amino acid).17 Here, tRNA (serine-tRNA) is 
aminoacylated by an amino acid “precursor” (serine, Ser) by a non-discriminating AARS (serine-tRNA 
synthetase, SerRS) and further converted to Sec by another enzyme (selenocysteine synthase).18 This was 
first found when an archaeal genome was fully mapped.19,20 Since the genome only contains 16 (out of
20) AARS sequences, the rest of AA-tRNA complexes are produced by non-specific AARS charging.
18
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That includes charging of asparagine (Asn), cysteine (Cys), glutamine (Gin) and lysine (Lys). For 
example, glutaminyl-tRNA synthetase (GlnRS) is not found in archaebacteria but also in Gram-positive 
eubacteria, or eukaryotic organelles.11 For tRNAGln to be charged by Gin, glutamic acid (Glu) is first 
attached to form Glu-tRNAGln. This product is taken by GluRS amidotransferase that catalyzes the 
removal of the ammonia group from glutamine and transfers it to a substrate that forms a new carbon- 
nitrogen group. Resulting tRNAGln is charged with Gin (Gln-tRNAGln).18 It is not clear why there are 
organisms with alternative pathways of tRNA charging. The question is why we find some examples that 
lack certain types of AARS in nature and therefore possibly require energy or extra molecules in order to 
complete protein synthesis.
tRNA 5'
NH.
O —
NH.HO
Figure 2: AA-tRNA. Amino acid is attached to the 
3' tRNA terminal site at 2’OH group of the ribose.
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AARSs are not only essential for protein biosynthesis but also provide high selectivity, so that they 
are able to join a specific amino acid with a specific tRNA molecule. This very precise system depends 
mostly on the AARS’ ability to distinguish the right substrate from the other competing noncognate 
substrates. An error rate for AARSs was determined to be about 1 in 10,000.11 This high specificity is 
due to a large number of contacts between AARS and amino acid or tRNA. Therefore, removing a part 
of the key synthetase structure or only a crucial residue mutation, could result in a high level of 
aminoacylation errors, which is catastrophic for any biological system.11 The mechanisms by which 
AARS achieves high fidelity are at the centre of this project.
There are a large number of synthetases available for analysis and comparison.13 Therefore, the 
interest in studying AARSs has been increasing for decades. That is obvious from the amount of research 
conducted since the early 80’s. High-resolution crystal structures of AARS coupled with tRNA, amino 
acid or a different substrate analogue are widely available now.21'24 Exploring these structures helps in 
the understanding the protein-nucleic acid interactions. Improvement of crystallization techniques 
together with biochemical and genetic studies are reasons why we can now understand much more about 
AARSs expression, structure, function and specificity. From this understanding, one can hardly think of 
how a biological world could exist without synthetase enzymes.11
Scientists have been analyzing AARSs not only to expand their structures and functions but so they 
might understand the regulation of gene expression. Synthetases are the link between the nucleic acid 
code and amino acid chain. It has been observed that AARS and tRNA directly or indirectly control gene 
expression.13
On a profound level, large numbers of AARS’s can be investigated, compared and used for 
evolutionary analysis since they represent a large class of enzymes with similar functions.13 Synthetases 
are ancient proteins25 and their phylogenetic trees can be compared.18 Even though their functional 
similarities are obvious, these do not reflect their structural framework. For instance, one question is:
20
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how two distinctive synthetase groups have evolved?18,25,26 By exploring of the standard molecular level 
of enzymes we can discover in depth the cell organization, how does the whole cell machinery functions
1 o
as well as how it has evolved.
2.1 Mechanism of aminoacylation reaction
In order to understand how a synthetase functions, the aminoacylation reaction will be described 
in more detail here. In Figure 4 the general mechanism of aminoacylation reaction is demonstrated with 
the incorporation of tryptophan (Trp) used as an example.11 Prior to the actual incorporation, the 
tryptophanyl-tRNA synthetase (TrpRS) is essential for the condensation reaction of Trp with ATP while
77 78forming a tryptophan adenylate (Trp ~ AMP) and releasing PPi. ’
TrpRS + Trp + ATP -► TrpRS:Trp ~ AMP + PPi 
In activated Trp ~ AMP, carboxyl group of Trp is linked to the phosporyl group of AMP ( Figure 3).
Figure 3: Structure of Trp~AMP. Trp~AMP is a mixed anhydride 
that is formed after condensation of Trp with ATP.
21
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After Trp is activated, incorporation of this amino acid is accomplished through a two-step reaction. 
In the first step, TrpRS which is bound to tryptophan adenylate (TrpRS:Trp ~ AMP) charges 
tryptophanyl-tRNA (tRNATrp) with Trp to generate a Trp-tRNATrp.28
TrpRS:Trp ~ AMP + tRNATrp -* Trp-tRNATrp + AMP + TrpRS
Figure 4: Mechanism of Trp incorporation.11
The overall aminoacylation reaction is:
Trp + ATP + tRNATrp -> Trp-tRNATrp + AMP + PP,
AG° of this reaction is close to 0 because the free energy of Trp-tRNATrp hydrolysis is similar to the 
free energy of ATP hydrolysis. The reaction is driven by hydrolysis of pyrophosphate and therefore is 
exergonic. In total, equivalent of two ATP molecules are consumed to form Trp-tRNATrp. 1 ATP is used 
to form the ester linkage between Trp-tRNA and 1 ATP is used as a driving force of the reaction.29
Trp-tRNATrp is in the second step brought to the aminoacyl (A) site of the ribosome by a translation 
elongation factor Tu.11 The A site is a place of peptide bond formation.
Trp + ATP AMP+PPi GDP+PI
elongation factor Tu
Trp-tRNA-rrptRNATrp
mRNA
3'
ribosome
22
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2.2 General features of aminoacyl-tRNA synthetases
It is important to note that even though AARSs provide the same aminoacylation reaction and use 
the same amino acid-like substrates, they display a high degree of diversity13 and dissimilarities in size, 
amino acid sequence, and their three dimensional structures.30 Using Escherichia coli (E. coli) as a 
model organism, it was found that the quaternary structure of synthetases follows up from monomers eg- 
isoleucyl-tRNA synthetase (IleRS) to tetramers alanyl-tRNA synthetase (AlaRS). In terms of primary 
structure, the length can range from as short as 334 amino acids (TrpRS) to as long as 1112 amino acids 
for the phenylalanyl-tRNA synthetase (PheRS). In native molecular mass we can find synthetases from 
51,000 Da cysteinyl-tRNA synthetase (CysRS) to 384,000 Da (AlaRS).25 Another variability relates to 
the number and structure of subunits in the synthetase structures. In this manner, a synthetase could form 
a monomer a, homodimer a 2 , homotetramer 0 4 , or heterotetramer CI2 B2 . Based on that, synthetases can be
13separated into four groups.
Sequence data based searching techniques31 have shown that 20 different AARSs are related to 
each other. Based on X-ray crystal structure, those were divided into two classes of 10 enzymes each: 
class I and class II (Table 1). The class distinction was firstly derived from crystal structure similarities 
of SerRS32 with aspartyl-tRNA synthetase/aspartic acid tRNA complex (AspRS:tRNAAsp)33 and 
homology of GlnRS34 to methionyl-tRNA synthetase (MetRS)35 and tyrosyl-tRNA synthetase 
(TyrRS).36,37 Class determination is based mainly on the active-site architecture shared by all members of
*> o
the same class, but also on additional domains attached to the central active-site domain with functions 
other than catalytic function. The type of an amino acid which is to be attached by synthetase to tRNA is 
crucial.26 AARSs of two classes undergo conformational changes of the active site in different manners 
while binding to a nucleotide substrate. In case of synthetase and tRNA recognition, the main identity 
determinants are distributed along tRNA, mainly the anticodon loop and the amino acid acceptor stem.
Each of the classes is further divided into three subclasses based on their tRNA acceptor stem
recognition. These subclasses are summarized and named alphabetically as la, b, c, and Ha, b, c.39 There
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is a similar manner of rotation and orientation of a synthetase around the tRNA acceptor stem axis 
between la and Ila, or lb and lib. TyrRS (Ic) and PheRS (lie) are unique in the orientation of tRNA 
binding and differ remarkably from all other synthetases of their classes. That also indicates how 
synthetases couple according to the stereospecificity of an amino acid they need to recognize. In case of 
lysyl-tRNA synthetase (LysRS), two distinct types were found: first one is a typical class I synthetase but 
the second has characteristic II class synthetase features.40
Class I synthetase members are monomers (la and lb) or homodiamers (Ic). It was shown earlier 
that only the MetRS has originally four subunits but is converted into a monomer active form by limited 
proteolysis.41 Class I also displays two short common consensus sequences ‘HIGH’ histidine-isoleucine- 
glycine-histidine (His-Ile-Gly-His)42 and ‘KMSKS’ lysine-methionine-serine-lysine-serine (Lys-Met- 
Ser-Lys-Ser)43, which indicate the presence of a structural domain, the nucleotide-binding Rossman fold 
(a parallel p-sheet nucleotide-binding fold26) of the active site.30 HIGH and KMSKS are positioned right 
in the place of ATP binding.26
Class II synthetases (dimers or tetramers) form usually an antiparallel P-sheet surrounded by a- 
helices and are characteristic for their three conserved motifs. Motif 1, which always involves a pro line 
residue (Pro) in the intersubunit contacts, is formed by a long a-helix linked to a p-strand and is involved 
in a dimer interface. Motif 2 contains two antiparallel p-strands linked by a long loop and in case of 
Motif 3 a P-strand is directly associated with an a-helix. Motifs 2 and 3 form a part of the active site and 
contain an arginine residue (Arg).26,30
On a molecular level, all amino acids structurally display an -NH 2 group followed by Ca and a - 
COOH group as a central core. But depending on their side chain we find one subgroup of the class I 
AARS capable of the activation only in presence of tRNA (Glu, Gin, Arg)44 and another subgroup 
specific only for aromatic amino acids (tyrosine Tyr, Trp). Whereas, the rest of I AARS charge aliphatic 
or sulphur containing amino acids (valine Val, lie, leucine Leu, Cys, Met). In one of the subgroups of 
class II AARS, the consensus sequence is significant at their amino termini and they activate a tRNA
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with charged amino acids (aspartic acid Asp, Asn, Lys). On the other hand for some of the II class 
AARS’, sequence similarities are at their carboxy termini and specificity is towards small and polar 
amino acids (Gly, Pro, threonine Thr, His).
Two classes were separated based on how each of the synthetases charges a tRNA with an amino 
acid. Class I aaRS would be selective towards 2’OH of a terminal adenosine of tRNA while class II uses 
3’OH (except of PheRS which attaches Phe on 2’OH).26
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Table 1: AARSs (class I and class II). Structural and functional differences of two classes.11,30
Characteristics Class I Class II
Members (subunit composition) Subclass la
ArgRS (a), ValRS (a), IleRS (a), 
MetRS (a, a2), CysRS (a), LeuRS 
(a, ap)
Subclass Ha
SerRS (a2), ThrRS (a2), ProRS 
(a2), GlyRS (a2), HisRS (a2), 
AlaRS (a)
Subclass lb
GlnRS (a), GluRS (a), LysRSl 
(a)
Subclass lib
AspRS (a2), AsnRS (a2), LysRS2 
(ai)
Subclass Ic
TrpRS (a2), TyrRS (a2)
Subclass lie
PheRS [(ap)2], AlaRS (a4), 
GlyRS [(aP)2]
Conservative motifs* 4>H<|>GH, TIGN (TrpRS) 
KMSKS
parallel (1-sheet (Rossmann fold)
(1) Motif 1
(2) Motif 2
(3) Motif 3
Active site topology parallel P-sheet (Rossmann fold) seven-stranded antiparallel 
P-sheet
Position specificity 2'-OH group 3'-OH group (PheRS is exception)
* Conservative residues are indicated with capital letters, <J> is any hydrophobic residue.
In chapter 3, our focus is on two Ic synthetases; TyrRS and its close structural homologue, TrpRS. 
Primarily, we want to compare them in order to relate their substrate specificity mechanisms.
2.3 Key features of aminoacyl-tRNA synthetase fidelity
Since the study of synthetase fidelity is our main objective, here we explore the synthetase active 
site and the mechanism by which this fidelity is accomplished.
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Although synthetases have large structural differences in their subunit sizes and quaternary 
structures, the aminoacyl adenylate is recognized by sequences located in the N-terminal half of the 
proteins. On the other hand, tRNA recognition relies on both, the N-terminal half and the C-terminal half 
of the sequences.27 In terms of the aminoacyl adenylate binding specificity for all synthetases, 
homologous residues are in charge of recognition of ATP, -NH2 and -COOH groups arround the Ca. 
Different unique residues would recognize specific features, such as the side chain. For instance, class I 
synthetases are characteristic for their HIGH42 and KMSKS43 motifs, which specifically recognize ATP. 
We know from MetRS and TyrRS crystal structure complexes with ATP that both histidine residues 
from HIGH play an important role in substrate activation by stabilizing the ATP phosphoryl groups in 
the transition state of the activation.45,46 Also in TyrRS, two lysine residues from KMSKS are stabilizing 
transition state, during tyrosine adenylate (Tyr-AMP) formation by strong interaction with PPi moiety, 
similarly as in GlnRS.34,46,47
All synthetases have developed high specificities towards their natural substrates. Therefore, 
protein expression can be accurate.11,48 The selection of one correct amino acid from a reaction of D- and 
L- amino acid optical isomers, precursors of amino acid biosynthesis or products of amino acid 
degradation is a challenge for a synthetase.49 Charging of an incorrect amino acid and its incorporation 
would greatly affect cell survival. Different mechanisms providing correct aminoacylation have been 
uncovered while studying synthetases.50'52 That does not include only recognition itself, but also editing 
(or proofreading), gene duplication and the use of alternative biosynthetic pathways. The degree of 
synthetase fidelity for a natural amino acid depends on charge and on how much the amino acid differs 
from its competitors in size so that binding energy is higher and binding tighter.48 For example, although 
Asp and Glu share some similarities with Asn and Gin, their corresponding synthetases are able to 
discriminate them based on additional restrictions. Further, the discrimination mechanism for some 
aliphatic amino acids such as Val, lie and Leu is different. Since these display large similarities between 
each other and there are only small differences in their potential binding energies, an additional
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53synthetase editing mechanism (double-sieving mechanism) is essential. For valyl-tRNA synthetase 
(ValRS), IleRS, leucyl-tRNA synthetase (LeuRS), an extra CPI domain insertion has been found54 to 
recognize and hydrolyze AA-AMP and misacylated tRNAs.55'58
The active site hydrogen bonding is crucial for synthetase fidelity. This intermolecular noncovalent 
interaction occurs between two electronegative atoms that share a proton.59 For instance, in C -  H •••• O, 
H is attached to an electronegative C atom (hydrogen-bond donor) and a hydrogen bond is formed 
between the positive charge of H and an electon lone pair of the O atom (hydrogen-bond acceptor). This 
well-established60 dipole-dipole interaction is commonly present in protein and nucleic acid structures. 
Hydrogen bonding is the main structure determinant and is the key element of protein folding and 
stability.61 On the other hand, an important hydrogen bonding interaction does stabilize the substrate 
transition state and influences the rate of the enzymatic reaction. According to a classical view, it has 
been well studied that complementary hydrogen bonds and salt bridges as well as hydrophobic 
interactions are the main elements of synthetase specificity.
2.4 Common ways to study AARS’s fidelity
The main theme to this work is investigating the fidelity of AARSs. Thus, it is important to 
understand first how this property has been defined and studied for more than 40 years. The fidelity of a 
synthetase has historically been determined by various in vitro techniques.63 Although there are a number 
of high resolution crystal structures that allow us to observe, on the molecular level, how a number of 
AARSs achieve fidelity, standard mutagenesis and biochemical assays were previously able to piece 
together the important AARS residues taking part in an amino acid and tRNA discrimination.
One standard technique to determine AARS’ fidelity involves standard steady-state pyrophosphate 
exchange and aminoacylation assays to determine the enzyme’s kinetics.63 Specifically, they measure 
substrate binding and product release, which helps to characterize enzyme activity.64 These methods
28
Introduction
allow taking a small amount of samples for easy and fast manipulation. Furthermore, large numbers of 
synthetase-tRNA samples can be tested and compared.65 Pyrophosphate exchange assay measures 
catalytic activity of synthetase-like enzymes forming enzyme-adenylate intermediates.66 In this assay, we 
can follow the rate of exchange of radioactive PPi into ATP. In such an assay, one typically reports two 
parameters, turnover number (A:cat) and Michaelis constant (Km)- The important feature of such an assay 
is that it allows one to easily compare one AARS to another although it may be a mutant or even from a 
different organism.
32For example, reaction rates of AARSs, in mixture with their cognate amino acids, [y- P]ATP 
(gamma-32P ATP) and inorganic phosphate, were measured67 by pyrophosphate exchange method and 
their stoichiometries determined (etc. TyrRS from Bacillus stearothermophilus, Bst TyrRS, binds only 
one aminoacyl adenylate per dimer). On the other hand, the aminoacylation assay evaluates the rate of 
AA-tRNAAA formation. This assay was used to determine the efficiency of a wild type (wt) and mutant 
TyrRS’s from Methanococcus jannaschii (Mj TyrRS) in tRNATyr recognition.68 Moreover, this enabled 
finding the important tRNA recognition residue (Asp286) in Mj TyrRS structure. In another example,69 
the aminoacylation assay helped to determine the main Trp recognition residue (Asp132) that also 
discriminates against Tyr, in Bacillus stearothermophilus TrpRS (Bst TrpRS) active site. Different 
studies have found Km for TrpRSs from various organisms. The Michaelis constant of the 
aminoacylation reaction catalyzed by human TrpRS-6xHis showed a Km = 7.4 pM with L-Trp.70 
Aminoacylation assays were also performed in order to determine the kinetic parameters for wt Bst 
TrpRS and its variants. Km = 1.6 ± 0.1 pM for the wt synthetase.69
Furthermore, adenylation and aminoacylation have been studied using fluorescence approaches.63 
For the fluorescence studies, the presence of an intrinsic or extrinsic fluorescence probe, as Trp, is 
required. Binding AARS with its substrate is usually accompanied by a change in fluorescence of the 
synthetase. In this way, one can study synthetase interactions, structure and folding. In this manner, 5-
29
Introduction
71OH Trp is incorporated into oncomoduline and changes in 5-OH Trp fluorescence enables one to study 
interactions with anti-oncomodulin antibodies.
Pre-steady-state kinetic methods measure the formation and consumtion of enzyme-substrate 
intermediate in the first milliseconds, until the steady-state is reached. These methods have been used for 
more detailed analysis of synthetase and tRNA single residues in specific steps of a reaction. Out of 
these methods, the most common is the rapid chemical quench assay. This assay measures rapid 
reactions that cannot be monitored by absorbance or fluorescence spectroscopy. The rapid quench 
method directly measures radioactively labelled reaction product. For example, by using radioactivate 
probes, a cognate synthetase misacylation rate between Val and lie was estimated to be as high as 1 in 5.
7 9  7 9Nevertheless, this rate was found to improve to 1:3000 due to a synthetase editing activity. ’
Other methods have been used to characterize AARS specificity. In our work, we use isothermal 
titration calorimetry (ITC). This is a good alternative to determine binding parameters74 and therefore 
specificity of a synthetase towards its substrate. ITC enables us to measure a released heat of reaction 
between protein and ligand. This gives the information about the binding equilibrium. Greater binding 
responds to lower value of dissociation constant (Kd). ITC was used for binding studies of the human T2 
TrpRS with two tryptophans, which are part of the VE-cadherin.75 This experiment helped to understand 
more about expanded functionality of the synthetase active site.
The in vivo complementation assay is another method we use in this project to investigate the 
specificity of synthetase. In this approach, a bacterial strain struggles to grow on a media deficient for an 
amino acid. Using such E. coli strain that required added Trp to grow well, Soil and coworkers69 studied 
a number of TrpRSs. This strain contains a mutation of TrpRS gene that destabilizes the synthetase 
structure and affects synthetase activity. Synthetase can only function in the presence of excess substrate. 
In this manner, different synthetase mutants expressed in the strain cell can be tested for their fidelity if 
they are able to complement the auxotrophic phenotype under Trp-starved conditions. Specificity of
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several TrpRS mutants were tested by complementation assay.69 Growth of the Trp auxotrophic strain 
was only restored if an active mutant TrpRS was provided.
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3. Introducing TyrRS and TrpRS
Although there are several classes of AARSs, each with its own specific nuances of mechanism, 
here we focus soley on the TryRS and TrpRSs. This is because these two AARSs have been used to 
incorporate the vast majority of all the NAAs incorporated to-date. Furthermore, we can review their 
background together because it is likely that these two enzymes share a common ancient ancestor, and 
as such concepts about the mechanism and fidelity of one AARS are often applicable and insightful 
for the other AARS.
From extensive literature, we know a lot about many TyrRS structures and their active sites.46 It 
is the most used synthetase for nonnatural amino acid incorporation.4 On the other hand, TrpRS 
displays high similarity to TyrRS structurally, therefore we can learn much from TyrRSs and apply it 
for the study of TrpRS. This is important because the vast majority of nonnatural amino acids have 
been incorporated using TyrRS mutants, and it is our contention that if we better understand TrpRSs, 
then it may be possible to incorporate NAAs with TrpRSs that might not be possible with the more 
common TyrRS systems.
Thus, one of the main objectives of this study is to explore the usage of a Bacillus subtilis TrpRS 
(Bs TrpRS) wt and one mutant in expanded genetic codes.
3.1 Exploring of TyrRS active site
The active site substrate binding has been well studied on TyrRS.46 This synthetase is also the 
best explored example in synthetase/amino acid discrimination.53 In 1982, very little was known 
about the catalytic mechanism and the energetics of TyrRS or any other synthetases but within five 
years, the situation changed thanks to site directed mutagenesis, crystal structures and powerful 
kinetic tools. At this point, the major focus was the importance of binding energies in enzyme
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catalysis reaction. In order to understand this reaction completely, we need to know all interaction 
energies between the enzyme and its substrate. Starting from binding energies, we can get an insight 
into how the activation energy is lowered and how equilibrium constants fit in, as well as learning 
how the specificity is determined by the enzyme. Binding energies were defined as “differences 
between ligand and receptor bound to water and ligand and receptor bound to each other” .46 Early 
work done on TyrRS helped to investigate methods for quantifying the strengths of enzymatic 
interactions and how they participate in catalysis and specific determination.46
Fersht and co-workers,77 analyzed how the hydrogen bond is important in enzyme substrate 
specific binding. As an experimental system, they used the TyrRS from Bacillus stearothermophilus, 
the structure of which was at that time already known. In an earlier work, they indicated eleven 
possible hydrogen bonds bound to the aminoacyl adenylate in the active site, from which eight amino- 
acid side chains underwent a site directed mutagenesis (Asp176, Tyr34, Asp38, Tyr169, Gin195, His48, 
Thr , Cys ). Additionally, some other important hydrogen bonding residues were indicated, and 
divided into subsites (Figure 5 )46 Some of these are hydrogen bond acceptors and others hydrogen 
bond donors.
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Figure 5: TyrRS active site residues divided into five subsites. Tyr-AMP complex is 
shown in its transition state and hydrogen bonds interacts between the substrate and 
important amino acid chains.36
With a choice of target residues for mutagenesis, one has to consider many factors. These 
mutations must not disrupt, or largely change, the protein structure. Ideally, if we introduce a 
mutation, a side chain is replaced so the size of the cavity is altered but the structure of an enzyme is 
able to tolerate this change.46 This “nondisruptive mutation” effect78 was proven on crystal structures
7 0  81 8 7  8 7of some mutants ' as well as from kinetic data. ’ Every mutation resulted in modification of a 
hydrogen bond, which helped to define its importance. The effect of the active site mutations was 
energetically measured in the activation reaction of Tyr and the mutant enzyme was compared to the 
wt enzyme. Such comparisons give direct information about a hydrogen bond importance in 
specificity and catalysis.83,84 For instance, deletion of a side chain that forms a hydrogen bond with
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an uncharged group on the substrate weakens binding energy by only 0.5-1.5 kcal/mol. Nevertheless, 
deletion of a residue side chain that interacts with a charged group weakens binding energy by 3-6 
kcal/mol. On the other hand, deletion of a group forming long hydrogen bond appends to an opposite 
effect and actually improves the binding. Analysis of the mutation effects helped to describe TyrRS 
subsites, interacting with the ligand, as follows.46
The tyrosine binding site comprises of residues specific for amino acid binding. Distinctively,
  I *70 -1 'TO
Tyr , Asp and Gin form their hydrogen bonds with -NH2 group of Tyr. If any of these residues is 
mutated, binding energy weakens by about 3 kcal/mol.77,85 Asp176 and Tyr34 have bseen indicated as 
residues of Tyr site chain specificity. Mutation of Tyr34 resulted in 0.5 kcal/mol energy loss, which 
indicates that the hydrogen bond between Tyr substrate and Tyr residue is relatively weak. On the 
other hand, Asp176 mutation produced an inactive enzyme. That makes Asp176 an extraordinary key
or
residue of Tyr specificity, as its carboxylate is a hydrogen bond acceptor of the substrate -OH group. 
Fersht further observed46 that Tyr34Phe mutation decreased discrimination for Phe substrate. Although 
only one -OH group is removed because of this mutation, the effect on the specificity of Tyr/Phe 
recognition is significant. As was mentioned before, the energy of the hydrogen bond linking -OH of 
Tyr34 and a lone electron pair of the substrate Tyr oxygen is quite low. This is because Tyr ligand with 
its -OH group is a poor hydrogen bond acceptor. Therefore, Ku for the Tyr34Phe mutant in activation 
of Tyr increases only by a factor of two and the specificity for Tyr decreases by 15 fold. The 
importance of two residues Tyr34 (hydrogen bond donor) and Asp176 (hydrogen bond acceptor) was 
demonstrated on the wt TyrRS in an activation reaction of Phe.77 Usually, if the wt enzyme is not 
associated with a ligand, these two residues are hydrogen bonded to a water molecule. These bonds 
are broken when Tyr comes to the active site and new hydrogen bonds form between its -OH group 
and Tyr34 and Asp176. If Phe accommodates the active site, the binding energy is reduced by about 7 
kcal/mol.48 The reason is probably that the water molecule remains in between Tyr34 and Asp176, and 
this is causing some unfavourable interactions with the substrate for lack of a space. In summary, for
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the TyrRS to switch its specificity from Tyr to Phe substrate, two key residues Tyr34 and Asp176 need 
to be mutated.77 Normally, because of the great difference in initial binding energies of Tyr and Phe, 
TyrRS does not need any editing mechanism, as Phe is activated 1.5 x 105 times less efficiently than 
Tyr.48 This makes TyrRS highly specific towards its substrate Tyr.77
The TyrRS binds not only the amino acid chain, but also has a special region to bind the 
adenylate molecule. The ribose binding site has three important residues, Cys35, Thr51 and His48. 
These three contribute to stabilization of the enzyme:Tyr-AMP transition state. The result is that the 
binding energy of these relatively distant groups is used in catalysis to lower the energy difference
£T) 27 oqbetween the ground and transition state. ’
The ATP phosphates and pyrophosphate amino acid site require residues His45 and Thr40 which 
clearly bind and stabilize the gamma-(X)-phosphate of ATP in the transition state and PPi in the 
enzyme:Tyr-AMP-PPi complex.86,87,90,91 Different residues, Arg86 and Lys230 also bind to the ATP in 
the transition state and to the PPi, while Lys82 and Lys233 interact with the enzyme:Tyr-ATP 
complex.92
Thr51 is a nonconserved residue and therefore represents the evolutionary variation site of 
Rs/TyrRS.
3.2 Similarities between bacterial TyrRS and TrpRS
More than 15 years ago, it was observed that TyrRS and TrpRS I class synthetases are more 
linked to one another than any members of the same class.15,37,93 Because of the close homology, two 
synthetases were assigned to the Ic subclass. Carter and co-workers (1995) solved the X-ray crystal 
structure of Bst TrpRS in complex with tryptophanyl-5’AMP (Trp-5’AMP) to 2.86 A resolution and 
compared it to the structure of Bst TyrRS:tyrosyl-5’AMP (Tyr-5’AMP).85 The sequence identity 
between TyrRSs and TrpRSs is about 10-20%. Similarly, we can find the case of two TyrRS
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ortho logs from eukaryotic and bacterial organism or for two TrpRS orthologs.94 The crystal structure 
alignment of both structures indicates a high identity of tertiary structure and when comparing two of 
the sequences, the highest significance is found in their amino acid activation region (Figure 6).95 In 
particular, the TrpRS and TyrRS active sites interact similarly with adenine, ribose, -NH2 moieties of 
ATP as well as with the side chain of Trp or Tyr. In order to understand the mechanism of TrpRS 
specificity and catalysis, this similarity with TyrRS enables us to couple these two structures.
3.3 TrpRS molecular determinants compared to those from TyrRS
After having so much structural and kinetic information about Bst TyrRS, the question arises: 
How does the relation between TyrRS and TrpRS helps us understand how TrpRS gains its fidelity 
toward its substrate?
Before the crystal structure of TrpRS was known, only three other Class I synthetase structures 
were identified, and it was more difficult to find connections between synthetases, their mechanism of 
specificity and catalysis from data that was available. This was due to significant structural 
differences. Specifically, it was the structure of GlnRS with ATP and tRNAGln,34 MetRS with ATP,96
o r
and TyrRS with tyrosyl adenylate and Tyr known at the time. If we think about similarities between 
them, we can find a few important features. All three synthetases are united by the presence of their 
amino terminus Rossmann (dinucleotide) domain, with two characteristic consensus sequences, HIGH 
and KMSKS. HIGH motif contains Gly, which is a strictly conserved residue within all Class I 
synthetases and plays an important role in ATP adenine ring interaction.95 In addition, the Rossmann 
domain contains an insertion in between its first and second symmetrical halves. However, this 
insertion differs in size for TyrRS and GlnRS.34 Although TyrRS and GlnRS bind their substrates in a 
similar way, there are a number of active site unrelated interactions found for one enzyme but not for 
the other one.34 Furthermore, some similarities were found in the Ca backbone of the TyrRS and
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MetRS active site region but mostly TyrRS binds ATP in a different orientation than MetRS.96The 
variability of synthetases within the same class and the structure of their domains indicate diversity in
07
the recognition of their cognate tRNA respectively.
From Carter’s comparison of Bst TrpRS and Bst TyrRS active sites (Figure 6),95 interactions 
with the activated amino acid Tyr-5’AMP and Trp-5’AMP, were marked as almost identical. There is 
number of conserved residues that do not vary for both structures at all. Furthermore, TyrRSs and 
TrpRSs lack any sort of editing domain.
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Trp-5’AMP binds in the place of the Rossmann fold. The Rossmann fold, instead of a HIGH
1 7consensus sequence in case of TyrRS, comprises TIGN sequence in TrpRS. Gly from TIGN is a 
conserved residue and plays a role in ATP adenine ring recognition. As was mentioned earlier, this 
Gly has analogues in all other I class synthetases in similar positions. Other conserved interactions 
with adenosine phosphate were indicated as follows. Gin9 in TrpRS, which binds to the phosphate by 
its backbone amide, has its Asp38 analogue in TyrRS. 2’-OH and 3’-OH groups of the ribose in TrpRS 
are attached to Asp146, bound water, and the Gly144 backbone amide consistently as Asp194, water and 
Gly192 in TyrRS. Asn18 from the TIGN sequence of TrpRS interacts with ribose similar as His48 in 
HIGH of TyrRS. Other than adenosine phosphate, the -NH2 group of Trp also comprises interactions 
with Gin147 and Tyr125 identically to Gin173 and Tyr169 in TyrRS.
Despite these, there were some dissimilarities observed in the active site interactions. In TyrRS,
7 0
Asp hydrogen binds to the -NH2 of Tyr. Nothing similar is obvious in TrpRS. On the other hand,
1q i  1 01
Met and lie are interacting with the adenine 6-amino group with their carbonyl oxygen’s in the 
active site of TrpRS but are not found in TyrRS. Futhermore, in the TrpRS, Lys195 is hydrogen 
bonded to the a-phosphate of the adenylate. This Lys is part of the KMSKS loop, and needs to move 
~ 7.5 A in order to interact with the active site.95 On the other hand, distance residues in TyrRS: 
Lys230, Lys233 on one side of the pocket, together with Lys82 and Arg86 on the other side, are involved 
in tyrosyl adenylate formation.47
However, active site of two TyrRS and TrpRS is highly similar to each other, especially residues 
that recognize and specifically bind the amino acid. It was shown that residues Tyr125, Met129 and
132Asp form a specificity-determining helix in TrpRS, and are related to similar residues in an 
analogous TyrRS helix of Tyr169, Gln173and Asp176. For both synthetases, Asp132/Asp176 is a key 
residue of the side chain. The hydrogen-bond length of Asp with the side chain of the substrate is ~ 
2.8 A for both synthetases. If Trp binds to the TyrRS, it leaves an unfavourable gap of 4 A. On the 
other hand, Tyr binding to the TrpRS would result an unfavourable Van der Waals distance of ~ 1 A.
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The superposition of two TyrRS and TrpRS active sites indicated a slight, but important difference in 
Asp176/Asp132 residues position. Asp132 is placed closer to the Trp indole nitrogen with its -COOH 
group. Pro126 and Pro127 are important to provide this Asp132 recognition helix bend in the TrpRS 
active site. In terms of the side chain accommodation, Gin189 in TyrRS is replaced by Val141 in TrpRS 
so that there is an extra space for Trp indole ring. As mentioned, in TyrRS the Tyr34 is participating 
with its hydrogen bond to the substrate Tyr -OH group. One of the facts Carter and co-workers 
showed in detail was that for TrpRS/TyrRS, the main substrate identity determinants are identical: 
Asp132/Asp176. For the TrpRS to switch its specificity towards another amino acid, Asp132 or two 
prolines holding the Asp132 in a right position (Pro126 and Pro127) need to be replaced.95
The importance of the hydrogen bond interaction between Asp132 and Trp nitrogen hydrogen 
of indole in TrpRS was further tested.98 Replacement of the nitrogen by other heteroatoms (selenium, 
sulphur, of oxygen) resulted in translation inactivation. At the same time, the introduction of extra 
nitrogen close to the protonated nitrogen of indole did not result in a substrate, which was recognized 
(2-Aza-Trp). When position seven of Trp is replaced by nitrogen (7-Aza-Trp), this substrate is 
recognized and used by TrpRS.
3.4 Analysis of bacterial TrpRS: structure and mechanism of binding its 
substrates
For our purposes, it is best to focus on specific bacterial TrpRS structure and mechanism. Whilst 
there are of course human TrpRSs, the way they achieve fidelity is different from bacterial TrpRSs. 
Furthermore, expanded genetic codes are almost exclusively based on engineering or evolving 
bacterial TrpRSs and as such, they form the focus of our analysis.
Bs TrpRS as a member of the Ic subclass has a primary function to esterify 2’OH of tRNA ribose 
by Trp and produce Trp-tRNA. It is a homodiameric a 2 enzyme that contains the smallest subunit 
chains among known AARSs (330 amino acids long),99 it has been considered as an ideal candidate
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for studying structure function by means of site-directed mutagenesis.95 By comparing amino acid 
sequences, Bs TrpRS is 55.8% homologous to that of E. coli TrpRS (Ec TrpRS) and 78.1% to that of 
Bst TrpRS.99 TrpRSs share some similar features and a precise description was offered on Bst TrpRS 
homodiamer crystal structure.95 One monomer contains two unequal domains. A first central big 
domain comprises already mentioned the Rossmann dinucleotide-binding fold (1-200 residues). The 
Rossmann fold is made of parallel B-strands with a-helix crossover connections, which form a binding 
pocket for Trp and adenosine. Figure 7 shows a position of ATP in between BD and BE strands and 
aA and aE helices.24 Binding of the adenosine is afforded by TIGN and KMSKS motifs brought 
together by parallel B-sheet twist.37 Ribose is interacting with another identity determinant GXDQ 
(glycinexaspartic acid-glutamine), characteristic for Ic subclass. GXDQ is located at the N-terminus of 
aE.24 The Rossmann region also contains an amino acid sequence specifically binding Trp-tRNATrp 
acceptor stem." At the edge of the synthetase centre, a second small domain (SD) is built from four 
helixes (207- 280 residues), called a helix bundle. This is the region of high motion95 but also an 
anticodon Trp-tRNATrp binding site." One of the four helices expands along the whole monomer size 
and terminates at the dimer axis (265-326 residues).95 C-terminal Met and Met,92 that contribute in 
network of hydrophobic interactions, have the important roles in Trp pocket stabilization. 
Furthermore, Carter describes TrpRS domain movement while binding its substrates.100 When 
adenylate binds24 the SD together with the aA helix, TIGN, KMSKS and 175-182 residues move 
towards the active site in the Rossmann fold. After that, four chain segments (BD, BE, aA, aE) 
associate with the ligand. In a ligand free structure,100 aA helix moves about 13° away from the centre 
(aE and GXDQ) interacting with the helix bundle to form SD. Moreover, two consensus sequences 
and 175-182 residues move together with SD helixes by about 4-6 A and separates from the active 
site. In this manner, ATP binding site splits into two. Therefore, ligand free TrpRS structure is 
extended and larger. On the other hand, when Trp binds in the active site, four sides are involved: BA, 
the specificity determining helix; aD; the mobile loop/helix 106-117; and the C-terminal helix of the
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Rossmann fold. In a Trp free TrpRS, these four groups are slightly opened to allow Trp to enter. ATP 
and Trp can access a TrpRS active site independently and therefore either of them can be the first one 
to bind.
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Figure 7: C arter's Bacillus stearothermophilus TrpRS monomer crystal structure model.24
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3.5 Special cases of amino acid incorporation
As mentioned, there are now two well known, but rare instances of organisms using more that 
the common 20 amino acids. It is interesting and insructive for our work to note how these amino 
acids are incorporated into proteins by the host organism.
Incorporation of Sec and Pyl differs from the mechanism of the common 20 amino acids. Sec 
indirect pathway of acylation has already been descibed in chapter 1. Nevertheless, it was discovered 
that the incorporation of Sec was directed by the unique UGA codon.17,2 A similar situation was found 
in the case of Pyl. Pyl is a 22nd amino acid, found in bacterial species3 that was for the first time 
discovered in the Methanosarcina barkeri (M. barkeri).m  Since the incorporation of Sec,18 as 21st 
amino acid, does not involve a specific AARS rather than SerRS, pyrrolysyl-tRNA synthetase 
(PylRS) was assigned as the 21st AARS.102 Therefore, 21 is the total number of AARSs that have been 
discovered. PylRS was shown recently102 to be specific for the aminoacylation of pyrrolysyl-tRNA 
(tRNA1"71) by Pyl in Methanosarcinaceae. Such charged Pyl-tRNAPyl is specific for the unique UAG 
codon that is part of an open reading frame of a methyltransferase protein.3 Methyltranferases in 
general facilitate growth on methylamines as energy supplies. It’s thought that the incorporation of 
Pyl gives some evolutionary advantage to the organism.101 Furthermore, the M. barkeri Pyl-tRNAPyl 
pair was found to be an orthogonal pair in E. coli.m  Interestingly, Sec and Pyl incorporations take 
advantage of using unique stop codons.
Additionally,104 in some Candida species, the universal CUG codon, which normally 
encodes Leu, is reassigned to encode serine instead. Similar to these examples, using one of the 
unique codons (usually a stop codon) for a nonnatural amino acid incorporation in vivo, has become 
successful and popular in the sense of the expanded genetic code.105,5 This indicates that nature had 
already been using benefits of the unique codon for an amino acid incorporation long ago (etc. 3 
billion years ago for PylRS)21 before the engineered in vivo approach came to attention. In this in vivo
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approach, high specificity of a synthetase towards its substrates is achieved by a directed evolution of 
an ‘orthogonal’ tRNA synthetase/tRNA (AARS/tRNA) pair.106 NAAs in the expanded genetic code 
will be described in the next chapter, as it is the main subject of this thesis.
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4. Expanded genetic codes
Several methods of nonnatural amino acid incorporation have been developed in order to 
enhance properties of proteins by including additional NAAs in their structures. If such an amino acid 
is part of the peptide chain, it allows new ways to study the structure and function of proteins.105 
These methods have been divided as followed; in vitro or semi in vitro and in vivo methods (Table 2).
1H7 1 HQFor each of the methods, several advantages and disadvantages are defined. ’
For in vitro and semi-in-vitro manipulation, three common methods were assigned; chemical 
protein synthesis, chemical misacylation of tRNA and the import of AA-tRNA into eukaryotic cells. 
Within in vivo manipulations, we classify the use of amino acid auxotrophs and the use of orthogonal 
and new AARS/tRNA pairs. However, the primary focus of this work is on the usage of the last 
method (generation of an orthogonal and new AARS/tRNA pair) in the expanded genetic code. More 
specifically, we want to explore how the previously evolved76 mutant ifcTrpRS is orthogonal and 
specific for the use of nonnatural amino acid incorporation.
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Table 2: Methods of NAAs incorporation. Advantages and disadvantages of in vitro, semi-in-vitro and in vivo 
approaches.107,108
Manipulation Method Advantages Disadvantages
in vitro and semi-in-vitro
109Chemical protein synthesis
# incorporation of NAAs that are toxic to a 
cell or incompatible with translation
# insertion of isotopic labeled amino acids
# complex experiments
# low protein yields
# limitation in size of a 
peptide
# problems with solubility
Chemical misacylation of 
tRNA110
# amino acid incorporation at single 
predetermined positions
# cell free system
# complex misacylation 
experiment
# poor yield of 
aminoacylation reaction
# competition with host 
amino acids
# limited capacity o f a 
misacylated tRNA to fully 
decode a nonsence codon
# stability of mRNA and 
a new protein
Import of AA-tRNA into 
Eukaryotic cells111
# avoiding toxicity o f a NAA
# two different NAAs can be initroduced 
into the same
protein
# applicable for sensitive assays where a 
low amounts of modified protein is 
required
# complex misacylation 
experiment and further 
manipulations
# poor yield of 
aminoacylation reaction
in vivo
Use of Amino Acid 
Auxotrophs112
# small number of genome-wide 
mutations
# doesn't involve complicated 
manipulations
# high yield and fidelity
# high level of substitution 
and toxicity
# lack of control over 
natural substrate
# requires using of a very 
similar nonnatural analogue
Orthogonal and new 
AARS/tRNA pairs106
# high fidelity and efficiency
# high protein yields as a result of 
controlled heterologous expression 
systems
# position-specific incorporation
# minimal suppresion-associated toxic 
effect
# bad acceptance o f some 
"exotic" amino acids for the 
cellular permease system
# complicated mutagenesis 
and selection cycles
# metabolic toxicity
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Chemical protein synthesis is one of the methods that enables a peptide to be chemically 
synthesised with a NAA in the structure. Two main approaches have been widely used in this method: 
classic solution synthetic chemistry and solid-phase peptide synthesis (SPPS)113,114 In both cases the size 
of the peptide that is synthesised is limited to 30 - 50 amino acids.1 Other issues were described; mainly 
that purity and yield of the peptide were decreased. For synthesis of longer constructs, protected 
segments of a peptide can be coupled or a chemical ligation of nonprotected purified sequences is 
applied (Figure 8).’16 This method is more efficient and provides a synthesis of proteins < 30 kDa. Since 
the chemical ligation uses the Cys residue at the peptide bond formation site, at least one Cys must be 
present at the ligation site.
Peptide 2Peptide 1
T ransthioesterification
Peptide 2
Peptide
S —* A'acyl shift
H
H —  it —
I
H
Peptide
HS
o N
e T l/^ \N/
Peptide 2 K
Figure 8: Chemical peptide ligation.116 This method requires two unprotected peptides. Petpide 1 displays a 
C-terminal a-thioester and Peptide 2 an N-terminal cystein residue. In the first reaction -  
transthioesterification, peptide bond is formed between the N-terminal thiol (Peptide 2) and the a-thioester 
(Peptide 1) groups by nucleophylic attack of the thiol group. This reaction is followed by nucleophylic attack 
of the primary amine in S —>N acyl shift. In this fashion, Peptide 1 and Peptide 2 are joined together.
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In another approach, a chemically synthesised peptide containing a NAA is coupled to a biosynthetically 
produced protein. In this fashion, the position of substituent is limited only to N or C terminus.117 The 
outstanding issues o f chemical protein synthesis are in general limited by the size of the peptide and the 
extracellular environment. Additionally, the peptide synthesis by ligation reaction is restrained by a Cys 
residue o f the peptide site.105
Different methods of the nonnatural amino acid incorporation are based on the process of 
translation. This is when tRNA molecules associate with the genetic code in mRNA and the amino acid 
chain forms. Through a general in vitro biosynthetic method, a NAA can be successfully incorporated 
into a peptide. In principal, tRNA is “chemically misacylated”118 by a NAA and specifically recognizes 
one of the stop codons misplaced in a DNA sequence. This is attained in a cell free system.7,119 In a 
different approach, a cell system is used when misacylated tRNA is injected into Xenopus oocytes (semi- 
in-vitro method).111,120 For both, the formation of the tRNA associated with the amino acid is complex 
and there is low protein yield after expression.105
The use of auxotrophic organisms is an alternative in vivo approach for nonnatural amino acid 
incorporation. This approach has some benefits, when compared to chemical synthesis or in vitro 
biosynthetic methods as it does not involve complicated manipulations, also yields and fidelity are 
higher. Moreover, it enables us to study modified proteins in vivo and in vitro. One condition is that the 
NAA must be a close homologue to a natural one so that the tRNA synthetase is able to recognize it and 
misacylate the tRNA.121 The limitation of this method is the lack of control over competing natural 
substrates. In addition, such a method has a character of multiple sites substitution. Therefore, the use of 
an auxotrophic strain helps to inhibit the natural substrate incorporation, because such strain is unable to 
synthesise it.122 However, this method is limited for the requirement of a very similar nonnatural 
analogue.105 Some analogues were incorporated after relaxation of tRNA synthetase fidelity through 
active site mutations123 or by decreasing synthetase editing activity.124
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The methods that are most relavent to the work in this thesis are the methods that rely on 
suppression by an orthogonal and new AARS/tRNA pair with nonsense, rare or 4 base pair codons has 
brought success for nonnatural amino acid incorporation into proteins. This method is able to provide 
high fidelity and efficiency and likewise more than 70 NAAs have been site-specifically incorporated
110  17^ 1 90  1 90  199into proteins in vivo. ’ ‘ That includes amino acids with novel functional group, 
photocrosslinkers,133 heavy atoms and redox active moieties. Three requirements of the method are: a 
unique (an orthogonal) tRNA-codon pair, corresponding aminoacyl-tRNA synthetase (an orthogonal 
synthetase), and a NAA. In principle, an orthogonal synthetase recognizes and aminoacylates a specific 
orthogonal tRNA with the NAA. Afterwards, this tRNA is brought to the ribosome and the NAA is 
inserted in frame with the growing peptide in response to the rarely used codon (Figure 9). The 
orthogonal tRNA must not be charged by any o f the endogenous synthetases, just as the orthogonal 
synthetase must be precise in a specific recognition of only the orthogonal tRNA molecule. Besides, the 
orthogonal tRNA must be only charged by the NAA to the unique stop codon, and this codon must not 
be recognized by any other endogenous tRNA’s. Furthermore, the orthogonal synthetase must only 
charge the tRNA with the NAA and not any of the 20 common amino acids. In the same way, the rare 
amino acid must not be a substrate for cellular synthetases. At last, the transport of the NAA needs to be 
cell permeable and must not be toxic or a target for degradation by cellular enzymes.107,134
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Figure 9: Nonnatural amino acid incorporation in vivo. The orthogonal synthetase specifically 
aminoacyletes the orthogonal tRNA with the NAA. tRNA with NAA are brought to the A-side unique stop 
codon of the ribosome. In this manner, NAA is incorporated into a peptide chain.
The generation of an orthogonal and new AARS/tRNA pair in the expanded genetic code has 
brought some challenges. Initially, E. coli and its AARS/tRNA (Ec AARS/Ec tRNA) pair were used as a 
target for nonnatural amino acid incorporation. However, this approach did not find complete success 
due to endogenous tRNA’s misaminoacylations by designed Ec AARS.135 Nonetheless, the same year a 
paper was published by Furter with a more effective approach.136 In this work a yeast PheRS/tRNAphe 
pair was used to incorporate p-fluoro-phenylalanine (p-F-Phe) in dihydrofolate reductase (DHFR) in E. 
coli. In principal, p-F-Phe as an external added amino acid, is activated by yeast PheRS in a p-F-Phe- 
resistant-Zs. coli strain and incorporated in place of a “blank” amber stop codon. The p-F-Phe-resistant-Zs. 
coli strain consists of Ec PheRS mutants that are able to exclude p-F-Phe substrate from the substrate 
binding. This incorporation was preferred (11-21 fold) to the endogenous Phe or Lys incorporations. The 
PheRS/tRNAPhe orthogonality, high specificity and a good protein yield after expression were a good 
start of the in vivo incorporation methods enhancement.
An important contribution that would allow many of the shortcomings in these early orthogonal 
systems to be overcome came from Schimmel and co-workers (1999). These workers carried out some 
studies of the archeal Mj TyrRS and found that due to the absence of a second domain, including the 
anticodon recognition site, the synthetase only had a minimal anticodon recognition ability.137 This is
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important because most synthetases, especially the ones in Schultz and Further’s early studies, would 
have been detrimentally affected as a consequence of recoding the anticodon loop of the tRNA from the 
standard anticodon to an anticodon for a stop codon. This is because the tRNA anticodon loop is an 
important identifying element for most AARSs. Thus, Schimmel’s results showed that this specific 
synthetase lacked any interaction with the anticodon loop, and this had a lot to do with the fact that Mj 
TyrRS are now the most widely used AARSs in the expanded genetic code. Another important 
discriminatory factor is the first base pair of the acceptor stem. In the case of the bacterial tRNA, it is 
G1:C72 base pair, whereas eukaryotic and archeal organisms have C1:G72 pair in the same place. For 
that reason, Mj TyrRS is able to recognize and charge eukaryotic tRNATyr but not Ec tRNATyr. Besides, 
it was shown that in the structure of tRNA the variable arm is another key discriminator.138 As a result, 
Furter’s and Schimmel’s work strongly supported the idea of orthogonality as a powerful tool for the 
expanded genetic code.
A significant change in the method efficiency was brought by introducing an orthogonal 
AARS/tRNA pair from archaea M. jannaschii for use in the E. coli cells. The wt of this pair, chosen by 
Schultz a co-workers,106’ 125 is originally incorporating Tyr (Mj TyrRS/A// tRNATyr) and was chosen 
based on Schimmel’s observations about anticodon loop recognition. When used in E. coli, there is no 
interaction between the orthogonal Mj TyrRS and Ec tRNATyr or Ec TyrRS and Mj tRNATyr but the new 
Mj TyrRS/A^' tRNATyr pair is efficient in translation.139
In order to incorporate the NAA at a specific site, a choice of a suppression codon needed to be 
considered. Since translation in E. coli is usually terminated by two stop codons, UGA and UAA in 93%, 
UAG amber stop codon was an ideal choice to use for an analogue suppression. In this order, Mj 
tRNATyr anticodon site was mutated to CUA so that it specifically binds to the UAG in mRNA.
To improve specific aminoacylation of Mj tRNATyr by only Mj TyrRS, 11 tRNA nucleotides were 
selected and randomized by mutagenesis. Result of this was the generation of a suppressor tRNA library. 
These mutants were passed through rounds of negative and positive selection. In the negative selection,
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cognate synthetase is not present and an amber suppression codon is located in the area of barnase gene 
of toxicity. If tRNA is aminoacylated by an endogenous Ec TyrRS then ribonuclease barnase is the 
product of barnase gene suppression. This product is lethal for cells so the only surviving colonies should 
contain appropriate suppressor tRNA, or non-functional tRNA. Cognate synthetase is included in 
positive selection for the remaining tRNAs that follows this negative selection. This time, an amber 
codon is present in B-lactamase gene. When cognate synthetase specifically aminoacylates tRNA, B- 
lactamase gene is suppressed and cell gains its resistance towards ampicilin. Cells with tRNA 
nonspecific to the cognate synthetase or containing a non-functional tRNA will lack antibiotic resistance. 
After selection rounds, resulting mutant tRNA (mutRNATyrcuA) is able to restore cell antibiotic 
resistance by providing full B-lactamase suppression but is also preferably aminoacylated by Mj TyrRS 
as by Ec TyrRS. Mj TyrRS together with mutRNATyrcuA {Mj TyrRS/mutRNATyrcuA)5 with a high fidelity 
and low background of unspecific suppression, is an ideal orthogonal pair.106
Besides that, cognate Mj TyrRS needs to be evolved into an orthogonal synthetase that specifically 
recognizes a NAA.106 Considering the crystal structure of Bst TyrRS,85 five active site residues important 
for ligand binding140 were chosen to be randomised by mutagenesis and a library of all possible Mj 
TyrRS mutants (1.6><109) was created (Figure 10). Yet again, positive and negative rounds of selection 
were applied to obtain the final orthogonal synthetase. In positive rounds, cells are co-transformed with 
two plasmids containing different Mj TyrRS mutants from a library and mutRNATyrcuA. The amber stop 
codon is introduced into the chloramphenicol acetyltransferase (CAT) gene.141 Cells are grown in the 
presence of a NAA and are tested for survival in different chloramphenicol concentrations. Surviving 
ones either contain synthetase mutant aminoacylating the NAA or natural amino acid. Those are chosen 
for negative selection and tested for a growth in the absence of a NAA. The negative selection of a 
synthetase includes a suppression of amber nonsence mutations introduced into the barnase gene. Hence, 
only those incorporating natural amino acid survive. Going back to colonies from positive selection
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plate, which did not survive in negative selection are the ones containing mutant Mj TyrRS most specific 
for nonnatural amino acid suppression.106,107
Figure 10: Bst TyrRS active site.
Stereoview shows the important amino 
acid specificity determining residues and 
Tyr ligand (blue.) Based on this structure,
Mj TyrRS active site residue analogues 
were randomized to select a synthetase 
mutant, specifically charging OMe-Tyr.106
Using the directed evolution scheme outlined above, the first NAA incorporated was O- 
methyltyrosine (OMe-Tyr). This method resulted in a highly specific AARS due to improved 
tRNA/synthetase pair orthogonality and because it involved directed evolution of a mutant tRNA and a 
synthetase library. Shortly after, the same Mj TyrRS was used to incorporate 3-(2-naphthyl)alanine in E. 
coli.142 Another orthogonal and new AARS/tRNA pairs have been derived from Mj TyrRS/A// tRNATyr 
pair. They displayed a high specificity towards different amino acid analogues, including Tyr-like or 
Phe-like4. Some of these are listed in Table 3.143
L eu  iso  
P h e i7 7
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Table 3: List of NAAs incorporated by AARS/tRNA pairs, derived from A//TyrRS/A//tRNATyr pair.
NAA Common name Organism(s) in which NAA 
is encoded
References
1 /j-acetyl-L-phenylalanine E. coli, yeast, mammalian cells 130 , 144-146
2 m-acetyl-L-phenylalanine E. coli 132
3 (di-ketone-containing analogue) E. coli 147
4 O-allyltyrosine E. coli 131
5 phenylselenocysteine E. coli 148
6 /7-propargyloxyphenylalanine E. coli, yeast, mammalian cells 145 , 146 , 1 4 9 ,1 5 0
7 p-azidophenylalanine E. coli, yeast, mammalian cells 144 -146 , 150 ,151
8 /7-boronophenylalanine E. coli 152
9 O-methyltyrosine E. coli, yeast, mammalian cells 106, 144-146 , 153 , 154
10 p-aminophenylalanine E. coli 155 , 156
11 /7-cyanophenylalanine E. coli 157
12 /7-iodophenylalanine E. coli, yeast, mammalian cells 128 , 144-146
13 /7-bromophenylalanine E. coli 128, 158 ,1 5 9
14 (isotopically labelled analogues) E. coli 10
15 /7-nitrophenylalanine E. coli 160
16 L-DOPA E. coli 161
17 3-aminotyrosine E. coli 162
18 3-iodotyrosine E. coli, yeast, mammalian cells 163, 164
19 /7-isopropylphenylalanine E. coli 155
20 3 -(2-naphtyl)alanine E. coli 142
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21 biphenylalanine E. coli 165
22 p-hydroxyphenyllactic acid E. coli 166
23 bipyridylalanine E. coli 165
24 HQ-alanine E. coli 167
25 /7-benzoylphenylalanine E. coli, yeast, mammalian cells 133 , 144-146, 154, 168
26 o-nitrobenzyltyrosine E. coli 169
27 2-nitrophenylalanine E. coli 170
28 (phenylalanine- 4 ‘- azobenzene) E. coli 171
29 (diazirine photocrosslinker) E. coli 9
30 (fluorescent analogue) E. coli 172
31 /7-carboxymethylphenylalanine E. coli 173
32 3-nitrotyrosine E. coli 174
33 sulfotyrosine E. coli 175
4.1 Directed evolution & fidelity of TyrRS
Primarily, a synthetase active site is responsible for an amino acid recognition and activation.176 
The whole idea of the expanded genetic code is based on orthogonal AARS fidelity. In other words, the 
orthogonal AARS active site must be highly specific towards the amino acid analogue and must no 
longer activate the cognate amino acid. To achieve fidelity, several rounds of positive and negative 
selection afford to select a synthetase that successfully acylates a NAA.
However, before positive and negative selection, an AARS’ active site is usually redesigned by site 
directed mutagenesis. Smith and co-workers (1978) first introduced site directed mutagenesis as a
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powerful in vivo method, which enables one to substitute a codon with a different codon.177 Thus, during 
translation in the place of this new codon, a new amino acid is introduced, that was not originally there. 
An amino acid can be substituted by any other 20 common amino acids. This method was also used77 to 
systematically mutate the active site residues of Bst TyrRS and follow the effect of each mutation in 
ligand binding. In this approach, it was crucial to examine the new amino acid chain’s contribution 
towards binding of a substrate. Next,106 based on the active site of homologous Bst TyrRS crystal 
structure, five important Mj TyrRS active site residues were chosen for mutagenesis (described in section 
4). These residues were mutated in order to create a library of all possible combinations of 20 amino 
acids, this is called saturation mutagenesis.107 The library of all mutants was passed through rounds of 
positive and negative selection. In this fashion, the best Mj TyrRS mutant was selected that specifically 
recognizes OMe-Tyr with high efficiency and translational fidelity.105
For a better understanding of orthogonal synthetase adaptability towards a nonnatural substrate, 
Schultz and co-workers crystallized Mj TyrRS in complex with /?-acetylphenylalanine (pAcPhe). This
^ 9 1 1  SOcrystal structure demonstrated positions of mutated residues (Tyr Leu, Asp Gly, lie Cys, and 
Leu162Arg), that change synthetase specificity towards the NAA (Figure 11). In the wt M. jannaschii
32synthetase, similarly as in Bst TyrRS, the ligand Tyr has its -OH group hydrogen bonded to Tyr and 
Asp158 residues. To facilitate a complete change of the TyrRS fidelity towards /?AcPhe, these two
1 no nn
hydrogen bonds had to be deleted by mutagenesis of the crucial Tyr and Asp residues. If Tyr and 
Asp158 would not be modified, synthetase specificity towards /?AcPhe would suffer a loss because of the 
remained Tyr ligand affinity. In other words, in order to completely change Mj TyrRS specificity from 
Tyr to pAcPhe, hydrogen bonds forming between Tyr32 and Asp158 and Tyr -OH group must be targeted 
by mutagenesis.
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Figure 11: Methanococcus jannaschii TyrRS 
active site. Residues Tyr32, Asp158, lie159, and 
Leu162 were mutated to Leu32, Gly158, Cys159, and 
Arg162, in order to change synthetase specificity 
towards /7-acetylphenylalanine (pink).178
4.2 Incorporation  of try p to p h an  analogues
L-Trp is a fundamental protein building block but at the same time is involved in the metabolism of 
some important molecules like hormones — serotonin or melatonin in animals, or indole alkaloids in 
plants. L-Trp and its derivates are targets of drug and antibiotic development.179 L-Trp is a source for 
most of the absorption and fluorescence observed in proteins. In globular proteins, tryptophans are 
unique as they represent only 1% of all residues of the protein sequence.4 Therefore, L-Trp has been used 
as a probe for fluorescence spectroscopy in order to study conformational changes180 of a protein as:
1 O |
folding/unfolding, substrate binding etc. A problem of data interpretation occurs if in a mixture of two 
proteins both comprised with a L-Trp residue, so it is difficult to distinguish between them. That is why 
L-Trp is not an ideal probe for biochemical interactions. In this case, one would look for a Trp analogue 
with a unique spectroscopic properties. However, it is very important that such an extrinsic probe have 
ideal properties so that it does not disturb protein structure and function.
Trp analogue incorporation into a native protein structure has been an important target of
1 SOstudying. Ideally with the incorporation, protein structure or function should not be perturbed. One 
approach is an in vivo expression using a Trp auxotrophic strain. This strain is not able to synthesize L-
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Trp by itself and contains a plasmid encoding a protein of interest under the control o f  inducible
promoter.127 Growth of the strain is attained in a media containing L-Trp. Cells are then harvested by
centrifugation and resuspended in a media supplied by a Trp analogue. Next, protein expression is
18^  • •induced and the Trp analogue is misincorporated in place of related L-Trp. Often this incorporation is
1 84toxic for bacterial growth if a structure of crucial proteins is changed by the presence of such species. ’ 
185 Each NAA displays a different level of toxicity. In the instance of Trp analogues, despite toxicity, 
several have been able to undergo incorporation into bacterial proteins. Namely, this involves fluorinated 
tryptophans,186,187 azatryptophans,185,188 methyltryptophans, and hydroxytryptophans.184 There is a great 
advantage of a Trp analogue that can be used in UV absorbance, fluorescence or 19F NMR.189-191 For 
example, if a Trp fluorophore integrates into a protein sequence during biosynthesis, a new spectrally 
enhanced protein (SEP) could be produced. This fluorophore has novel spectroscopic features and is
192distinct from other tryptophans. Trp analogues were confirmed to be useful for X-ray crystallography. 
Selenium-containing Trp was used to feed E. coli Trp-auxotrophic strain, to be incorporated into human 
annexin V and barstar. Two such proteins were crystallized and their structures solved. Trp with the 
electron-rich selenium was essential for phase determination in X-ray crystallography. Some Trp 
analogues as [6,7]-selenatryptophan, can be used as pharmacologically active substrates in proteins.98,126 
In order to obtain protein pH sensors, aminotryptophans were incorporated into a protein and showed a 
significant pH dependence UV shift. 164,165,177 180
Over the years, much work has been done on investigation of synthetase specificity towards more 
than one substrate. For example, one natural amino acid can serve as a substrate for two different 
synthetases as well as a wt synthetase is able to charge its cognate tRNA with a NAA.4 Incorporation of 
7-azatryptophan (7-azaTrp) and 2-azatryptophan (2-azaTrp) was achieved in E. coli in 1956.185 Shortly 
after that it was already clear that TrpRS from the pancreas is responsible for activation o f some Trp 
analogues.193 In 1968, Schlesinger reported that an auxotroph E. coli strain is able to grow on 7-azaTrp 
or 2-azaTrp and produce an active alkaline phosphatise.194 In 1970,184 Trp auxotrophic B. subtilis strain
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was able to restore its growth on substrates like 5-methyl-tryptophan (5-M-Trp), 5-hydroxytryptophan 
(5-OH Trp), and 7-azaTrp which were radiolabeled. This experiment showed that after a Trp starvation 
period, when one of the analogues was added, the aminoacyl incorporation was renewed. Therefore, 5- 
M-Trp, 5-OH Trp, and 7-azaTrp are able to substitute Trp (5-OH Trp = 7-azaTrp < 5-M-Trp) although, 
by this substitution a certain level of toxicity is seen. In addition, a competition experiment between Trp 
and its analogues followed. When cells are grown in the presence of 5-OH Trp, they incorporate 5-OH 
Trp, but if an additional Trp is supplied they stop the analogue incorporation immediately. In addition, 
even large amounts of 5-OH Trp or 5-M-Trp did not inhibit the Trp incorporation, when this one is 
present in media in a small amount. In this study, 5-OH Trp was also indicated to act the same way as
1 Rf\Trp in the pathway for the biosynthesis of aromatic amino acids. In 1975, Pratt and Ho emphasized 
growth of an E. coli strain on different fluorotryptophan (F-Trp) analogues. These analogues were 
incorporated into E. coli enzymes lactose permease, ^-galactosidase, and D-lactate dehydrogenase that 
resulted in different levels of activities. In the presence of 4-fluorotryptophan (4-F-Trp) about 75% of 
Trp was replaced in cellular protein by the 4-F-Trp. In case of 5- or 6-fluorotryptophan (5-F-Trp, 6-F- 
Trp), 50-60% of Trp was replaced by these analogues. The enzymes restored their activities best if they 
contained 4-F-Trp in their structures. A couple of years later, in order to replace three tryptophan 
residues by 5-OH Trp’s in X cl repressor, Ross (1992) used an E. coli auxotroph and achieved 95%
127efficiency. The same year, 5-OH Trp was incorporated into oncomodulin by in vivo expression using 
an auxotroph E. coli strain.71 In another report from Hogue and Szabo (1993) it was suggested195 that if 
7-azaTrp or 5-OH Trp are incorporated into proteins, they must have been forming an 
aminoacyladenylate in Bs TrpRS. Based on the spectroscopic properties of the analogues, these 
enzyme/aminoacyladenylate complexes could be analyzed. 7-azaTrp adenylate or 5-OH Trp adenylate 
were indeed shown to be bonded to Bs TrpRS and it was appreciated that there is a great benefit in 
studying protein structure and dynamics of these complexes. Laue196 and Senear197 used in vivo 
incorporated 5-OH Trp as an intrinsic probe for studying of protein-nucleic acid interaction between
61
Introduction
DNA and bacteriophage lambda cl repressor. Nevertheless, James et al. incorporated 5-OH Trp into 
transferrin and its receptor, using the mammalian expression system. In this manner, a fluorescence
198changes could be monitored when iron was released.
A second approach is an in vivo transcription-translation using stop codon suppression, which was 
described earlier in this thesis (section 4). In comparison with TyrRS, directed evolution of TrpRS has 
been neglected199 and yet TrpRS does belong to the same Ic class and so it is very similar to TyrRS. 
Therefore, the main advantage for TrpRS, as for TyrRS in terms of directed evolution approach, is the 
lack of the editing domain and the active site residues recognition dependence. Moreover, TrpRS active 
site binds Trp, the largest natural amino acid, and for this reason has a potential for the incorporation of 
large NAA.200 For this reason, a new orthogonal TrpRS/tRNA pair from Saccharomyces cerevisiae was 
evolved for use in E. coli}99 Earlier, Schultz and co-workers76 introduced a new B. subtilis TrpRS 
Val144Pro/tRNA (Bs TrpRS Val144Pro/i?s tRNATrpucA) pair that specifically recognizes 5-OH Trp in 
mammalian cells. However, we found this last example (“Selective incorporation of 5- 
hydroxytryptophan into protein in mammalian cells”) in conflict with previous work done on directed 
evolution of TyrRS’s and in vivo Trp analogue incorporations by native TrpRS’s using auxotrophic 
strains. Thus, the next section is primarily focused on problems associated with this report, which is also 
the main focus of this project.
4.3 Selective incorporation of 5-hydroxytryptophan into protein in mammalian 
cells
5-OH Trp was chosen as a target for incorporation into a protein structure (Figure 12).76 5-OH Trp 
is a derivative of L-Trp. It is an absorption and fluorescence probe with an absorption band at lower 
energies than the absorption of tryptophan. Proteins containing such a probe are able to be distinguished 
even if they display number of L-Trp residues.71 These spectroscopic properties together with redox 
properties give a useful tool to probe the protein structure in vitro and in vivo}6
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Figure 12: 5-hydroxy tryptophan structure.
The previous report claimed to have incorporated 5-OH Trp in response to the opal codon UGA,
into bacteriophage T4 fibritin {foldon) domain, in mammalian cells (human kidney 293T) with more than
97% fidelity.76 In order to achieve this, they76 intended to generate an orthogonal Bs TrpRS Val144Pro/i?s
tRNATrpucApair. The report referred to Yokoyama et al., who incorporated 3-iodo-L-Tyr in mammalian
cells with 95% fidelity by generating a heterologous orthogonal pair consisting of a B.
stearothermophilus amber suppressor tRNATyr and mutant Ec TyrRS.201 Furthermore, they referred to
Xue et al., who described that Bs TrpRSARstRNA is orthogonal in yeast and mammalian cells.202
Therefore, they76 firstly modified Bs tRNATrp sequence for eukaryotic translation, expressed and tested
by Northern blot assay. In order to find out if wt Bs TrpRS is orthogonal and charges only the suppressor
Bs tRNATrpucA, the in vitro aminoacylation assay was applied. Only this tRNA was found to be charged
by a L-Trp whilst, as a control, the total tRNA isolated from mammalian tRNA remained uncharged.
Next, they tested that the Bs TrpRS/i?s tRNATrpucA pair is suppressing an opal mutation stop codon
UGA68 within mammalian cells. A resulting full-length foldon protein was compared to the wt foldon
protein and other controls on SDS/PAGE followed by Western blot. It was concluded from these
experiments that Bs TrpRS IBs tRNATrpucA acted as an orthogonal pair for use in mammalian cells. The
last approach was to create a Bs TrpRS that would specifically aminoacylate the suppressor Bs
tRNATrpucA with 5-OH Trp. Because the crystal structure of Bs TrpRS had not been solved, a crystal
structure of similar TrpRS tryptophanyl-5’AMP complex from B. stearothermophilus95 was taken by the
63
Introduction
report76 as a model to choose which active site residue to mutate. The main emphasis was directed 
towards the active site a-helix peptide comprising of residues Asp140, lie141, Val142, Pro143, Val144, and 
Gly145. If 5-OH Trp were to be positioned into the active site pocket in the same manner as is L-Trp as 
shown in the crystal structure, its 5-OH group would be pointing towards Val144, which makes this 
interaction unfavourable. For this reason, they picked Val144 as a target for site-directed mutagenesis to 
find an ideal residue that would be smaller and therefore better for 5-substitued Trp analogue 
accommodation. Altogether 19 different amino acid variants were generated by mutation of Val144. Next, 
they were tested if they are able to suppress the UGA in the mutant foldon gene in presence of 1 mM 5- 
OH Trp. Furthermore, the report stated that one mutant, Bs TrpRS Val144Pro, was capable of this 
suppression and there was no foldon protein product gained in absence of 5-OH Trp or tRNATrpucA 
(verified by Western blot). High-resolution elestrospray ionization mass spectroscopy, fluorescence 
spectroscopy and cyclic voltammetry, applied on the mutant foldon gene, were other methods used by
7 f \the group to prove the presence of 5-OH in the mutant protein. To facilitate crosslinking of two 
monomers containing 5-OH Trp into a dimer, an electrochemical approach was applied and the resulting 
products separated with SDS/PAGE. On behalf of all of this, it was concluded that Bs TrpRS Vali44Pro 
mutant efficiently aminoacylates tRNATrpucA with 5-OH Trp and not any other endogenous amino acids 
and, thus, is capable of efficient opal stop codon suppression. According to the report it was startling that 
only one mutation was able to change the whole Bs TrpRS specificity from L-Trp to 5-OH Trp.
It was concluded76 that this mutation had a significant impact on Bs TrpRS fidelity. In order to 
explain that, the active site of the Bs TrpRS Val144Pro*5-OH Trp-5’AMP was modelled based on already 
known wt Bst TrpRS'L-Trp-5’AMP (PDB ID 3FIO)95 (Figure 13). In this modelling 5-OH Trp is 
orientated differently to L-Trp so its indole ring flips over ~ 180° and Val144Pro mutation opens more 
space for this accommodation. Such a position allows the indole nitrogen, to be hydrogen bonded to Ser . 
5’ OH group of the 5-OH Trp forms new hydrogen bonds with Asp133 and His44.76
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Modelling of the complex between TrpRS and its substrates using 
INSIGHT II
Tl*4
IM*
Wild type BsTrpRS«Trp-5’AMP
complex
Val 144ProBsT rpRS»5HTPP-5 ’AMP 
complex
Zhang Z. et.al. PNAS 2004:101:8882-8887
Figure 13: Model of Bs TrpRS Val144Pro»5-OH-5’AMP built from wt Bst TrpRS»L-Trp-5’AMP, by previous 
report.76
4.4 Analysis of Bs T rpR S
The nonnatural incorporation method, that uses the orthogonal AARS/tRNA pair, faces two 
challenges. It is to achieve a high translation fidelity and efficiency, comparable with translation of the 
common amino acids. What does high translation fidelity and efficiency of the NAA incorporation really 
mean?
The translation fidelity is primarily linked to an AARS and its ability to specifically charge its
substrate. While nearly all o f the NAAs incorporated by Mj TyrRS mutants are poor substrates for wt
AARSs, their incorporation in vivo depends mainly on a development of a new orthogonal tRNA
synthetase pair. A new orthogonal synthetase needs to not only provide great fidelity for the tRNA
aminoacylation reaction but also discriminate all the 20 common amino acids. Ideally, in nonnatural
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amino acid suppression, the NAA will have a different chemical structure from any natural substrates. It 
is more challenging to achieve a high specificity of the orthogonal synthetase towards the analogue if 
this one is too similar to the original substrate. In this case, there is a higher chance that the analogue 
will be recognized by the endogenous synthetase.106
The efficiency of the NAA suppression is determined from the amount of the full-length 
protein produced after the suppression. If a NAA is incorporated in place of the UAG suppressor stop 
codon, translation is efficient and a full-length protein is produced. On the other hand, if NAA 
suppression fails and translation terminates in UAG, a truncated protein is produced. Therefore, the 
efficiency of the NAA incorporation is the ratio of full-length protein versus truncated protein in the 
presence of the NAA. A number of factors, such as the concentration of NAA in the media, are related 
to translation influence its efficiency. Firstly, it is the orthogonal AARS competency to adenylate NAA 
and charge the orthogonal tRNA. Other important factors are the release factor-1 (RF-1), concentration 
of the NAA, transport and metabolism of the NAA, elongation factor Tu (EF-Tu) and post-translation 
modifications.
It was reported that Bs TrpRS Val144Pro mutant synthetase incorporated 5-OH Trp, in response 
to the opal stop codon, in mammalian cells. This was achieved with 20% - 40 % suppression efficiency 
and 97% fidelity76 (Figure 14). For most nonnatural amino acid incorporations, the suppression 
efficiencies vary between 25% - 75% and translation fidelity is >99%. In addition, protein yields after 
expression usually range from several milligrams to tens of milligrams per litre of a cell culture.105 
Incorporation of amino acid analogues in an eukaryotic system is more difficult to achieve. The main 
issues usually are the orthogonal tRNA expression and its translational competency as well as the 
orthogonal synthetase evolution. Moreover, the mammalian cell system is more challenging in terms of 
the protein expression.5
Nevertheless, our concern is: does the suppression by mutant Bs TrpRS Val144Pro really display 
high fidelity and efficiency in the mammalian system as was reported? The reason for this concern is
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that Bs TrpRS Vall44Pro mutant is not the outcome of a standard library selection for 5-OH Trp 
analogue.
Lane
Vall44ProBsTrpRS 
mutRNA I ca
5-HTPP 
Mutant TrpRS"1 »
Foldon-His6
Figure 14: Result from the Schultz’s and co. report (Western blot of the cell extracts with an 
anti-V5 antibody). 6 Incorporation of 5-OH Trp by Bs TrpRS Val144Pro mutant into the foldon 
protein. The report used this experiment to show that in the absence of 5-OH Trp, tRNArrpUCA, or Bs 
TrpRS Val144Pro, there is no full length protein produced (lanes 1-4). On the other hand, if those 
three are present in the cell, the full-length foldon protein is produced.
Furthermore, the original report 6 stated that the wt Bs TrpRS does not use 5-OH Trp as a substrate 
and so it is essential to evolve a new Bs TrpRS suppressor tRNATrpucA pair if one wants to integrate this 
Trp substituent in a protein structure. From previous work listed in section 4.2, it is obvious that 5-OH 
Trp is a substrate in cells that they can utilise with the wt TrpRS. It was demonstrated that the wt, 
bacterial12 and human198 TrpRSs (including Bs TrpRS184) are able to recognize and charge 5-OH Trp 
if it is present in growth media (global 5-OH Trp incorporation) (Figure 15). In this incorporation, 5-OH 
Trp is introduced at all L-Trp sites. Nevertheless, if only a small amount of L-Trp remains in the media, 
incorporation of the natural substrate is preferred to 5-OH Trp.184 Figure 15 shows, that if 5-OH Trp is to 
be incorporated at one permissive site (UGA), a new orthogonal TrpRS/tRNAIrpucA pair needs to be 
introduced into the cell.
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This is a different situation as many examples of TyrRS directed evolution. M. jannaschii TyrRS wt 
does not normally display an affinity towards any of the nonnatural substrates that are now regularly 
encoded. The affinity towards NAA, m case of TyrRS examples, is gained by directed evolution in the 
active site of the synthetase. In this manner, TyrRS loses its affinity towards a natural substrate.
cell
1. Known process o f the global
5-OH Trp incorporation in 
human cell line E. coli.
+ 5-OH Trp -L -T ip  
Wild type TrpRS.
cell
protein
Incorporation at ALL L-Trp sites.
2. Site-specific incorporation 
of 5-OH Trp.
+ 5-OH Trp
Orthogonal TrpRS tRNAsoirnpucA 
pair.
cell
protein
Incorporation at one (UGA) permissive
site.
Figure 15: 5-OH Trp incorporation in a human cell line or E. coli. 1 - Global 5-OH Trp incorporation
according to James198 in human cell line and Ross127 in E. coli, with no L-Trp access (- L-Trp). 5-OH Trp is
incorporated at ALL possible L-Trp sites. 2 - 5-OH Trp could be specifically incorporated at one 
permissive site (UGA), if the orthogonal TrpRS/tRNATrpucA pair is in charge.
If one investigates the active site of a normal wt TrpRS, one can see quite readily, why the active wt 
TrpRS would still be expected to incorporate a substrate like 5-OH Trp. This is an important detail of our 
work because we essentially argue that there was a fatal flaw in their research design, and this was the 
fact that the human TrpRS would be expected to competitively incorporate both 5-OH Trp and L-Trp
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into all cellular proteins. This may be the reason for Schultz and coworkers choice of an obscure test 
system (i.e. their “foldon” protein) which had just one Trp residue. Had the protein had two or more Trp 
residues, one could have its corresponding codon mutated to the opal codon and targeted for 5-OH Trp, 
whilst both 5-OH Trp and Trp- would have been competitively targeted to the other L-Trp residues 
precisely because the endogenous TrpRS has a reasonably high affinity for 5-OH Trp. Again, this latter 
point has in fact been proven for several bacterial TrpRSs and even human TrpRSs, where it has been 
shown that the endogenous wt TrpRS, in the presence of lower L-Trp concentrations, will incorporate 5- 
OH Trp into all proteins.
The fact that the 5-OH Trp might be incorporated into all proteins does not by itself negate the 
utility of the Schultz study, because one can imagine a scenario where it would be advantageous to site- 
specifically incorporate 5-OH into a protein. However, our work and analysis goes much further and 
strongly suggests that even the targeted incorporation of 5-OH Trp at a reprogrammed opal stop codon 
would proceed preferentially at L-Trp and not the NAA. We will discuss at length how we came to this 
conclusion, but the real explanation is no more complicated than understanding that a key molecular 
determinant from Schultz’s Bs TrpRS mutant is still located in the same position that the residue is found 
in the wt enzyme.
The hydrogen bond’s importance in the molecular determination was already described in chapter 
3. Active site synthetase residues are responsible for the substrate specificity of synthetases. They bind 
the substrate with hydrogen bonds and discriminate against non-substrates. As was studied the Bst 
TrpRS structure95, the Asp132 residue is hydrogen bonded to the tryptophan indole nitrogen and is 
important for L-Trp recognition.98 This makes the Asp132 the main molecular determinant in the Bst 
TrpRS active site. Structurally 5-OH Trp is very similar to L-trp and the only difference is the presence 
of the -OH group in position 5 of 5-OH Trp. Despite this, the structure of the indole ring with nitrogen 
remains the same for either L-trp or 5-OH Trp. For this reason, we suggest that the recognition of these 
two ligands by Bs TrpRS active site Asp133 (equivalent of Asp132 in Bst TrpRS) residue happens in the
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same manner. This was already confirmed when wt Deinococcus radiodurans TrpRS {Dr TrpRS) was 
co-crystallized with 5-OH Trp. The position of the analogue indole ring did not change and remained 
similar as L-trp in the crystal structure of the same synthetase (PDB ID 2A4M)203 (Figure 16). Therefore, 
the indole nitrogen of 5-OH Trp is hydrogen bonded to the aspartate carboxylate group Asp157 
(equivalent of Asp132 in Bs TrpRS) in Dr TrpRS.
Aspi57
Figure 16: W t Deinococcus radiodurans TrpRS active site crystal structure model with L -trp (left) and 
5-OH T rp (right). Nitrogens are indicated in blue, and oxygens red. In both, indole nitrogens points towards 
the Asp1' carboxylate group.
The original report 6 explained 5-OH Trp accommodation by modelling the Bs TrpRS Val144Pro*5- 
OH Trp-5’AMP active site (Figure 13). 5-OH Trp flips over by 180° and original hydrogen bond 
between the indole nitrogen and Asp133 disappears. This suggests that this model disagrees with what 
was shown in the Dr TrpRS crystal structure, where position of 5-OH Trp does not change comparing to 
the natural substrate. Moreover, the active site of Bs TrpRS Vall44Pro mutant comprises an unmodified
133 •Asp ~ residue that is the major L-trp or 5-OH Trp determinant. Therefore, the burden is twofold as the 
synthetase mutant must suppress the enzyme’s affinity for L-Trp and 5-OH Trp and switch the enzyme’s 
fidelity to only 5-OH Trp.204
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76It was also stated (unlike in Mj TyrRS approach) that for selective incorporation of 5-OH Trp into 
proteins, the Val144Pro mutation is enough for enzyme to switch its specificity so that it does not use L- 
Trp. This is because Val144 points towards the 5 position of L-Trp in wt Bs TrpRS synthetase and clashes 
with the 5-OH group of 5-OH Trp.76 However, in the TyrRS directed evolution,205 usually 4-8 active site 
residues needed to be randomized to create a TyrRS library. Next, a new TyrRS mutant was selected 
from the library and displayed a high fidelity towards its nonnatural substrate. However, the original 
report76 did not consider the directed evolution approach. Instead, Val144 was site directly mutated to 
each of the other 19 amino acids. These 19 Bs TrpRS mutants were assayed for their specificity to 
aminoacylate tRNATrpucA with 5-OH Trp. After this test, it was concluded that mutant Bs TrpRS 
Val144Pro, specific for 5-OH Trp incorporation displays high efficiency and translation fidelity.
Previous reports showed that one mutation of an active site residue was not enough for a synthetase 
to change its fidelity towards a nonnatural substrate, unless an auxotrophic strain was used. For 
instance, a Thr415Gly mutation in yeast PheRS resulted in site specifically incorporation of 6- 
chlorotryptophan, 6-bromotryptophan, 5-bromotryptophan, and benzothienylalanine.206 However, for 
this attempt to be successful, Phe-auxotrophic strains were used so that the level of the natural amino
• 901acid was very low and Phe was not competing the activation of analogues. Yokoyama and co-workers 
engineered Ec TyrRS to specifically recognize 3-iodo-L-tyrosine and not L-Tyr in aminoacylation 
reaction. As in the B. stearothermophilus (Tyr34), the identity determinant Tyr37 is hydrogen bonded to 
Tyr -OH group in the wt Ec TyrRS. This residue was chosen for mutagenesis together with Gin179 and 
Gin195, which are highly conserved among the prokaryotic TyrRS species. The effect of each mutation 
was examined separately, by randomising those three residues. By introducing one mutation in the active 
site, the most of mutants remained higher or the same activity towards tyrosine in comparing to 3-iodo- 
L-tyrosine. Two mutations enhanced the synthetase specificity towards the nonnatural substrate, 
especially in case of TyrRS Val37Cys195. Yet SDS-PAGE analysis shows that full-length protein is 
produced, even if 3-iodo-L-tyrosine is not present. That indicates that the fidelity of TyrRS Val37Cys195
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toward the nonnatural analogue is only moderate. That is why if only one mutation in a synthetase active 
site is to be applied for incorporation of a NAA, using either auxotrophic strain or depleted media 
conditions is necessary to achieve a high fidelity. This was not the case when the single mutant Bs TrpRS 
Val144Pro was used for 5-OH Trp incorporation.76
What is the impact of Val144Pro single mutation in Bs TrpRS? We know that the Val144 is not the 
major determinant of L-Trp specificity. In Soil’s work69, activities of different Bst TrpRS single mutants 
were studied, including a Val141Gln mutant. Val141 is a residue located in a similar region as Val144 in B. 
subtilis. This Val141Gln mutant has its catalytic efficiency reduced -300 fold for L-Trp and -1000 fold 
for ATP. Therefore, it is more likely that the activity for ATP is affected in Bs TrpRS Val144Pro most. 
There is no reason to think that this mutant would have changed its activity only towards 5-OH Trp. 
Recently, Schimmel and co-workers75 were able to disturb L-Trp recognition by human TrpRS 
completely by targeting an important recognition residue (Asp133-like in Bs TrpRS). Therefore, such a 
disruption is essential for Bs TrpRS to discriminate L-Trp or 5-OH Trp initially. The single Val144Pro 
mutation in the Bs TrpRS Val144Pro mutant does not convince us about this synthetase high 
discrimination ability. Hence we ask how a 97% fidelity, and good protein yields were obtained with Bs 
TrpRS Val144Pro mutant synthetase for 5-OH Trp incorporation in mammalian cells?76
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5. Our hypothesis
Fundamentally, in our approach we examine the impact of the Val144Pro mutation in Bs TrpRS. We 
contend that at least one main identity determinant (Asp132) was not randomized and has the same 
importance as Asp158 {Mj TyrRS) or Asp176 {Bst TyrRS) for the natural substrate recognition especially
76as no approach towards mutagenesis of this residue was considered in the original work.
Reflecting on the reports we have previously discussed, there is a chance that Bs TrpRS Val144Pro 
mutant would comprise an affinity towards the natural substrate. This would suggest a low fidelity of Bs 
TrpRS Val144Pro mutant, which is contradicting the original report. In addition, the Val144Pro mutation 
might have the potential to reduce a catalytic efficiency of Bs TrpRS.
5.1 Experimental approach
AARS fidelity can be tested and measured by many standard techniques (section 2.4). Since a 
critical analysis of the original work76 raises questions, the aim of our project is to directly evaluate the 
TrpRS enzymes using standard in vitro and in vivo techniques.
First, we wanted to crystallize the Bs TrpRS Val144Pro mutant in the presence of L-trp and 5-OH Trp 
because, based on the solved crystal structures, we would like to inspect the mutant synthetase active site 
and the effect of Val144Pro mutation. We are also attempting to see which of two competing ligands 
specifically binds in the active site and their orientation. In this manner, we hope to confirm the known 
mechanism of amino acid recognition by these synthetases.
Next, we wanted to apply a complementation assay by using E. coli tryptophan auxotrophic strain. 
Through this method, we hoped to find if an exogenous synthetase (either wt Bs TrpRS or Bs TrpRS 
Val144Pro) is able to charge E. coli tRNATrp with either L-trp or 5-OH Trp and therefore complement 
depleted phenotype under L-Trp-starved conditions.
73
Introduction
Finally, we wanted to measure wt Bs TrpRS and Bs TrpRS Val144Pro affinities towards L-Trp and 5- 
OH Trp by ITC. In this way, we want to examine their binding abilities towards both substrates and to 
indirectly measure the fidelity.
Through these three approaches; crystallography, complementation assay and ITC we wanted to
76reinvestigate the conclusions found in the original report. This is for the sake of understanding the role 
of fidelity and what is required for these enzymes to achieve it, as it is the key element for highly 
efficient nonnatural amino acid incorporation. We also wanted to confirm our hypothesis, that the Bs 
TrpRS Val144Pro mutant is likely a low fidelity synthetase.
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6. Material
6.1 Cloning and expression vectors
In this work, the following cloning and expression vectors were used (Table 4):
Table 4: Cloning and expression vectors
Vector Antibiotic/Resistance Tag
Copy
Number
Application
1. GS43463 pBSK 
3871 bp (Epoch Biolabs)
Ampicillin (AmpR) - High Custom synthesis o f Bs TrpRS Val144Pro
2. pET151/D-TOPO 
5760 bp (Invitrogen)
Ampicillin (AmpR)
V5,
N-term 6><His
Low
Cloning o f the synthetase genes wt Bs TrpRS and 
Bs TrpRS Val144Pro
Protein expression of wt RsTrpRS, Bs TrpRS Val144Pro and 
Bs TrpRS Val144Pro + tag
3. pGPl-2
7140 bp (LGC Standards)
Kanamycin (KanR) - Low
T7 polymerase expression; T7 polymerase facilitates a gene 
expression in pET 151
1. GS43463 pBSK (Epoch Biolabs) - pBlueScript II SK is a high copy number vector with a pUC origin 
of replication (Figure 17). It is commonly used for cloning, DNA sequencing, RNA transcripts in vitro 
production, site-directed mutagenesis and gene mapping. This vector contains an extensive polylinker 
with 21 distinguished restriction sites. T7/T3 RNA promoters that margin the polylinker, can be used for 
in vitro RNA transcription. Part of the vector is also lacZ gene fragment that enables the insert detection. 
The ampicillin resistance is achieved by presence of bla ORF. pBlueScript II SK can be also replicated 
as a ssDNA because it comprises the fl phage origin of replication.
GS43463 pBSK containing the Bs TrpRS Val144Pro insert was used for side-directed mutagenesis of 
Prol44Val.
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Figure 17: GS43463 pBSK
2. pET151/D-TOPO (Invitrogen) -  it is a low copy number vector with a pBR322 origin (Figure 18). In 
order to facilitate a low copy replication, rop ORF interacts with pBR322 origin. Furthermore, the vector 
contains T7 promoter, lac operator (lacO), ribosome binding site (RBS), ATG initiating codon, 
polyhistidine (6><His) region, V5 epitope, TEV recognition site, T7 reverse priming site, bla promoter, 
ampicilin {bla) resistance gene, lacl ORF. The presence of Tllac  promoter enables a high level, IPTG- 
inducible expression. Both, 6*His and V5 epitope fusion tags together with TEV recognition site are N- 
terminal oriented. Lacl ORF inhibits the basal gene transcription. pET151/D-TOPO is designed for 
cloning of blunt PCR products.
pET151/D-TOPO is used as a cloning and expression vector. In the complementation assay, pET151/D- 
TOPO is combined with a compatible kanamycin resistant pGPl-2.
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Figure 18: pET151/D-TOPO
3. pGPl-2 (LGC Standards) is a medium copy number plasmid with pl5A origin of replication (Figure 
19). This plasmid contains T7 polymerase gene which transcription is under the PL promoter. The 
temperature sensitive cI857 repressor controls T7 polymerase expression which allows non - BL21(DE3) 
strains to be used.
pGPl-2, producing T7 polymerase, used with pET151/D-TOPO facilitated expression of a gene 
synthetase in pET151/D-TOPO.
X(35,259) \(35 ,711)
T 7 (3106)
pGPI 2
7140 bp
T7(5840) 
BamHI
p 15A
Figure 19: pGPl-2
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6.2 DNA template
Table 5: DNA template used in this study
DNA Description
Bs TrpRS Val144Pro
1092 nt
(Sequence I)
• Bs TrpRS Vall44Pro (in GS43463 pBSK) was purchased from Epoch Biolabs 
and used for the site directed mutagenesis
• Bs TrpRS Val144Pro (in pET 151 /D-TOPO) was obtained by cloning and 
used for protein expression, complementation assay and ITC
wt Bs TrpRS
1092 nt
(Sequence II)
• wt Bs TrpRS was obtained by site-directed mutagenesis of 
Bs TrpRS Val144Pro (in GS43463 pBSK) and used for cloning
• wt Bs TrpRS (in pET 151/D-TOPO), obtained by cloning, was used for 
protein expression, complementation assay and ITC
Bs TrpRS Val144Pro 
+ tag
1167 nt
(Sequence III)
• Bs TrpRS Val144Pro + tag in (pET 151/D-TOPO) was obtained from ET* and 
used for protein expression and crystallization
* Dr. Eric M. Tippmann
Sequence I, II and III are given in Appendices
6.3 Bacterial strains
For all DNA and protein strategies done in this work, following strains were used:
Escherichia coli One Shot® TOP 10 (Invitrogen): F' mcrA A(mrr-hsdRMS-mcrBC) (p80/«cZAM15 
AlacXIA recAl <?raD139 A(ara-leu) 7697 galU galK rpsh (StrR) end A l nupG X-. This strain was used as 
a host for cloning of Bs TrpRS Val144Pro, Bs TrpRS Val144Pro + tag or wt Bs TrpRS genes and plasmid 
propagation.
Escherichia coli GeneHogs® (Invitrogen): F" mcrA A(mrr-hsdRMS-mcrBC) 80/acZAM15A
lacX14 recAX end A l araD\?>9 A(ara-leu)l697 galU galK X rpsL(StrK) nupG. This strain was used as a 
host for cloning of Bs TrpRS Val144Pro, Bs TrpRS Val144Pro + tag or wt Bs TrpRS genes and plasmid 
propagation.
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Escherichia coli One Shot® BL21 Star™ (DE3) (Invitrogen): F' ompT hsdSn Ob'me’) gal dcm rnel31 
(DE3). This host was used for Bs TrpRS ValI44Pro, Bs TrpRS Val144Pro + tag or wt Bs TrpRS genes 
expression.
Escherichia coli KY4040 (Coli Genetic Stock Center): F-, tyrT58{AS), trpS44, mel-1. This strain was 
used for the complementation assay, when strain was double-transformed with pET151 Bs TrpRS Val144Pro 
/pGPl-2 or pET151 wt Bs TrpRS /pGPl-2.
6.4 Enzymes
Table 6: Enzymes used in this study and their suppliers
Enzyme Supplier
Platinum® Taq DNA Polymerase Invitrogen
Dpnl restriction enzyme NEW ENGLAND BioLabs
B-Agarase I NEW ENGLAND BioLabs
Pwo DNA polymerase Roche
EconoTaq PLUS DNA polymerase Lucigen® Corporation
Topoisomerase I Invitrogen
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6.5 Kits
Table 7: Kits used in this study and their suppliers
Kit Supplier
QIAquick® PCR Purification Kit (50) QIAGEN
e.Z.N.A.1M Gel Extraction Kit OMEGA Bio-Tek
Zyppy™ Plasmid Miniprep Kit ZYMO RESEARCH
QIAprep® Spin Miniprep Kit (50) QIAGEN
Champion™ pET Directional TOPO® 
Expression Kit
Invitrogen
6.6 Chromatography columns
Table 8: Chromatography columns used in this study
Resin Supplier
Nickel-nitrilotriacetic acid (Ni-NTA) agarose Qiagen
Superdex 75 100/300 GL Amersham Bio sciences
Superdex200 100/300 GL Amersham Bio sciences
6.7 Media and supplements
All media components were usually ordered from MELFORD or SIGMA-ALDICH.
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Luria-Bertani (LB) medium
1 % Bacto Tryptone 10g
0.5 % Yeast extract 5 g
1 % NaCl 10 g
ddH20 Up to 1 litre (pH 7.5)
Luria-Bertani (LB) agar
1 % Bacto Tryptone 10 g
0.5 % Yeast extract 5 g
1 % NaCl 10g
1.5 % Agar 15 g
ddH20 Up to 1 litre (pH 7.5)
2*YT medium
1 % Bacto Tryptone 16 g
0.5 % Yeast extract 10 g
1 % NaCl 5 g
ddH20 Up to 1 litre (pH 7.5)
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Super Optimal (SOC) medium
1 % Bacto Tryptone 20 g
0.5 % Yeast extract 5 g
5 M NaCl 2 ml
1 MKC1 2.5 ml
1 M MgCl2 10 ml
1 M MgSC>4 10 ml
1 M glucose 20 ml
ddH20 Up to 1 litre (pH 7.5)
49 minimal medium
Stock solutions Final concentration in media
25 % NaCl 0.5 %
100 x Metal salts 1 x
50 % Glycerol 1 %
1M MgCl2 0.05 mM
20 mg/ml CaCl2 0.02 mg/ml
20 mg/ml Biotine 0.08 mg/ml
20 mg/ml Thiamine 0.08 mg/ml
10 x M9’s 1 x
0.1 M Leucine 0.3 mM
In order to achieve high sterility, media were either autoclave for 20 minutes/121°C or filter (Millipore) 
sterilized (0.4 pm pore size).
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6.8 Antibiotics
All antibiotics were purchased from MELFORD.
Table 9: Antibiotics used in this study
Antibiotic Stock solution Final concentration in media
Ampicillin 1 0 0  mg/ml in H2 O 1 0 0  pg/ml
Carbenicilin 1 0 0  mg/ml in H2 O 1 0 0  pg/ml
Kanamycin 50 mg/ml in H2 O 50 pg/ml
6.9 Oligonucleotides
Oligonucleotides were designed in EditSeq and SeqMan. The annealing temperature (Tm) was 
determined with the online Finnzyme Tm calculator. Oligonucleotides were synthesized and 
lyophilizated by IDT (INTEGRATED DNA TECHNOLOGIES). Obtained oligonucleotides were 
usually dissolved in dcftO to the final concentration 100 jiM, aliquoted and stored in - 20°C.
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Table 10: List of used oligonucleotides
ID Sequence Tm [°C]
Oligonucleotides used for overlap PCR
Prol44Val_F GATCTGGTCCCGGTCGGTGAAGACCAGA 69
Prol44Val_R GAT CCGT CCCGT AC AGC AG AT AT C 60
Oligonucleotides used for cloning into pET 151
TrpRSF C ACC AT G AAAC AG ACC ATTTT C AGCG 65
TrpRSR+stop TT ATT AGCGGCGTTT GCG ACCT AAAC 60
Oligonucleotides used for sequencing
T7F (invitogen) T AAT ACG ACT C ACT AT AGGG 48
T7R (invitogen) T AGTT ATT GCT C AGCGGT GG 52
M13F (invitogen) GT AAAACG ACGGCC AG 46
M13R (invitogen) C AGG AAAC AGCT AT G AC 45
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6.10 Software
Table 11: List of used programs, databases and bioinformatic tools
Name Link
BLAST http://www.ncbi.nlm.nih.gov/blast/
CCP4-6.1.3 http://www.ccp4.ac.uk/about.php
COOT-O.6.1 http://www.biop.ox.ac.uk/coot/
EditSeq http:// www. dnastar. com/t-sub-products -lasergene-editseq. aspx
ExPASy Proteomics Server http ‘.//expasy. org
Finnzyme Tm calculator https//www. finnzymes. fi/tm_determinati on. html
IC ITC http //www. cf. ac.uk/chemy/staffinfo/poc/software/ic itc/
MolProbity http://molprobity.biochem. duke, edu/
Molrep http://www.ccp4.ac.uk/html/ molrep.html
PROCHECK http://www.biochem.ucl.ac.uk/~roman/procheck/procheck.html
ProtParam http://expasy. org/tools/protparam. html
PubMed http://www.ncbi.nlm.nih.gov/pubmed/
PyMOL 0.99rc6 http://www. pymol. org/
RSCB Protein Data Bank http://www. r csb. org/ pdb/home/home. do
Refmac5 http JIwww. ccp4. ac. uk/ di st/html/re finac5 .html
SeqMan http ^ /www.dnastar.com/t-sub-products-lasergene-seqmanpro.aspx
Translate tool http ://expasy. org/tool s/dna. html
UNICORN 5.2 http://www.gelifesciences.com/aptrix/upp01077.nsf7Content/
aktadesign_platform~system_software
86
Material and Methods
7. Methods
7.1 DNA purification, concentration and sequencing
For plasmid and DNA purification, Zyppy™ Plasmid Miniprep Kit or QIAprep® Spin Miniprep Kit (50) 
were used. DNA concentration was determined by using nanodrop (Labtech International Ltd.). All 
DNA constructs were sequenced by Cardiff University DNA Sequencing Core, and analyzed in 
DNASTAR SeqMen program.
7.2 Mutagenesis
The 1012 bp DNA fragment (6.2) encoding Bs TrpRS with desired mutation Val144Pro was synthesised 
and provided in the GS43463 pBSK vector (6.1). Platinum® Taq DNA Polymerase PCR reaction (Table 
12), using two overlap PCR primers Prol44Val_F and Prol44Val_R (6.9), was designed to provide the 
CCC mutation of Pro144 into GTC Val144. After PCR, vector was digested by Dpnl restriction enzyme 
(6.4) and low melting agarose gel purified (7.2.3). This vector was transformed in Gene-Hog 
chemicompetent cells, which were incubated at 37°C overnight on 2YT agar plates with carbenicillin. 
Next, single colonies were picked from the plate and grown as 5 ml LB saturated cultures at 37°C 
overnight. DNA from every overnight culture was purified separately and its concentration measured. 
Furthermore, these DNA samples were sent for sequencing with M13F and M13R primers.
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Table 12: Overlap PCR reaction’s components and conditions
Overlap PCR1' of Bs TrpRS Val144Pro
PCR reaction components PCR reaction conditions
10*PCR Mg-free buffer 5 |il denaturing 94°C, 3 min
10 mM dNTP mixture 1 pi
denaturing 94°C, 30 sec
50 mM M gCf 1.5 gl
annealing 55°C, 30 sec 35 x
primer mix - Prol44Val_F and 1 gl
extension 72°C, 5 min/10 sec
Prol44Val R (10 |iM each)
final extension 72°C, 5 min
template DNAn) (100 ng/pl) 0.5 pi
Platinum® Taq DNA Polymerase 0.2 pi hold 4°C
(kftO Up to 50 pi
I) PCR was run on TC-3000 Personal 25-well Thermal Cycler
II) Sequence of DNA template is given in Appendices
7.2.1 Agarose gel electrophoresis
In order to visualize PCR or plasmid DNA samples, the agarose gel electrophoresis was used as a DNA 
presence detection method. 1 % agarose gel was prepared by warming 0.5 g agarose (Acros Organics) 
mixed with 50 ml l xTris-acetate-EDTA (TAE) buffer (AppliChem) in a microwave, until it completely 
dissolves. This agarose solution was cooled down to about 60 °C and Ethidium Bromide (BIO RAD) 
was added to the final concentration of 5 pg/ml so that DNA could be visualized on UV after 
electrophoresis. Next, the solution was poured into the casting tray and allowed to solidify. Before 
loading on the gel, the DNA samples (3-7 pi) were mixed with 6 X loading dye (10 mM Tris-HCl pH 7.6, 
60 % glycerol, 60 mM EDTA and 0.03% bromophenol blue) to the final concentration l x. Samples 
were loaded on the gel together with 1 kb DNA Ladder (BioLabs) in order to detect molecular weight of 
sample bands. Electrophoresis was usually run at 80-100 V in an electrophoretic chamber, for 30-90 
min. Gel, containing DNA bands was visualized with UV (VersaDoc™ Imaging System, BIO RAD).
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7.2.2 Dpnl digestion
In order to cleave the original DNA template in the PCR reaction, Dpnl digestion was carried on. Dpnl 
cleaves DNA recognition site that is methylated, lp l of Dpnl (20 U/ pi) was applied to the PCR tube, 
mixed, incubated for 1 hour/37°C and purified.
7.2.3 Low melting agarose gel purification
The entire PCR reaction was run on a 1 % low melting agarose (Promega) gel in order to separate and 
purify PCR product. A gel slice containing DNA band of a right size was simply cut from the gel and 
allowed to melt for 10 min in 70°C preheated water bath. Subsequently, this water bath was brought to a 
temperature of 42°C and 10* B-Agarase I Reaction Buffer (10 mM Bis-Tris-HCl, 1 mM EDTA, pH 6.5) 
was added to the final concentration lx. Futher, B-Agarase I was added, 1U (1 pi) for every 200 pi of 
melted agarose gel and left for 1 hour/42°C. The PCR product was purified with QLAquick® PCR 
Purification Kit (50) or e.Z.N.A.™Gel Extraction Kit.
7.2.4 Heat-shock transformation
Plasmid transformation was done by a heat-shock. One stock of chemically competent cells — 100 pi 
(stored in - 80°C) was first melted on ice. Next, 0.5 - 3 pi of a plasmid DNA was gently mixed with the 
cells and incubated for another 1 0 - 3 0  min. The mixture was then heat-shocked for 30 - 45 s in 42°C and 
cool on ice for 1 min. Cells were rescued by adding 200 — 500 pi of SOC media (6.7) and shaken for 1 
hour/37°C. Finally, the cell mixture was spread on the LB agar plate and incubated at 37°C overnight.
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7.3 Cloning into pET151/D-TOPO
The DNA fragment encoding wt Bs TrpRS (6.2) was amplified from GS43463 pBSK (6.1) by Pwo 
DNA polymerase PCR (Table 13) with TrpRS F and TrpRS R+stop primers (6.9). After PCR, fragment 
with CACC at the 5' end was low melting agarose gel purified (7.2.3). In order to express Bs TrpRS 
with 6 ><His tag at the N terminus in E. coli, the PCR fragment encoding the synthetase was ligated 
(7.3.1) into a pET151/D-TOPO vector (6.1), by using Champion™ pET Directional TOPO® Expression 
Kit (6.5). This construct was further transformed in E. coli One Shot® TOP 10 chemical competent cells 
(6.3). The cells were incubated at 37°C overnight on LB agar plates with 100 pg/ml carbenicillin. In 
order to check the presence o f the insert DNA in the TOPO vector, 6  colonies were picked and a colony 
PCR (Table 13) was carried on. For the colony PCR, EconoTaq PLUS DNA polymerase was used in a 
mixture of ready-to-use PCR EconoTaq PLUS 2x Master Mix and T7F, TrpRS R primers (6.9). The 
same colonies were inoculated in 5 ml volume of LB media with carbenicilin and grown at 37°C 
overnight. DNA from every culture was purified separately; its concentration measured and sent for 
sequencing with T7F, T7R and TrpRS R (6.9).
In the same manner, Bs TrpRS Val144Pro (6.2) was amplified (from Bs TrpRS Val144Pro + tag in pET151/D- 
TOPO) and cloned into pET151/D-TOPO.
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Table 13: Pwo DNA polymerase and EconoTaq PCR reaction’s components and conditions.
Amplification^ of Bs TrpRS Val144Pro and wt Bs TrpRS for cloning
into pET151/D-TOPO
PCR reaction components PCR reaction conditions
1 mM dNTP mixture
primer mix - T rpR S F  and TrpRS R (10 pM each) 
template DNA1^  (200 ng/pl),
10* PCR buffer 
Pwo DNA polymerase
ddH20
30 pi 
6 pi 
l p l  
15 pi 
1 pi
Up to 150 pi
denaturing 94°C, 2 min
denaturing 94°C, 15 sec 
annealing 60°C, 30 sec 
extension 72°C, 1 min/20 sec
30 x
final extension 72°C, 4 min
hold 4°C
Colony PCR1’
PCR reaction components PCR reaction conditions
EconoTaq PLUS 2X Master Mix 
primer T7F (100 pM) 
primer TrpRS R (100 pM) 
colony DNA 
(kftO
25 pi 
1 pi 
l p l
Up to 50 pi
denaturing 94°C, 2 min
denaturing 94°C, 30 sec 
annealing 60°C, 30 sec 
extension 72°C, 1 min/20 sec
35x
final extension 72°C, 2 min
hold 4°C
I) PCR was run on TC-3000 Personal 25-well Thermal Cycler
II) Sequence o f DNA template is given in Appendices
7.3.1 Ligation reaction
Directional TOPO® Cloning is based on a reverse reaction of Topoisomerase I phosphodiester cleavage. 
For ligation reaction of wt Bs TrpRS, Bs TrpRS Val144Pro constructs with pET151/D-TOPO vector (6.1), 
we used molar ratio 1 : 0.5 of PCR product:TOPO vector. The reaction, with total volume o f 6  pi 
contained 1 pi Fresh PCR product, 1 pi Salt Solution, 3.5 pi water and 0.5 pi TOPO vector. These 
components were mixed together, incubated at 22°C for 30 min, put on ice and used for transformation.
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1.4 Expression of mutants Bs TrpRS Val144Pro, Bs TrpRS Val144Pro + tag and 
wt Bs TrpRS
Starter cultures of E. coli One Shot® BL21 Star™ (DE3) (6.3), containing the pET151 with Bs TrpRS 
mutants or wt (6.2) were grown with vigorous shaking (210 rpm) at 37°C to an OD 0.6 - 0.9. Proteins 
were overexpressed after induction with 0.5 mM isopropyl-/?-D-thiogalactopyranoside (IPTG, 
MELFORD) for 4-5 hours.
7.5 Purification of Bs TrpRS-6xHis
Cells were pelleted by centrifugation at 4000 xg for 20 min (4 °C). A quantity of 1.5 g of wet cells from 
a250 ml culture was resuspended in 10 ml lysis buffer (50 mM NaH 2 PO, pH 8.0; 300 mM NaCl; 10 mM 
imidazole) and frozen overnight at -80°C. The cell pellet was thawed on ice. 1 mM protease inhibitor, 1 
mg/ml lysozyme and benzonase nuclease (2 pi / 250 ml starting culture) were added to the cells and 
mixed on rotator for 30 min, followed by sonication on ice. The lysate was centrifuged at 10,000 xg for 
40 min at 4°C to pellet the cellular debris. In order to purify the Bs TrpRS-6 xHis, nickel-nitrilotriacetic 
acid slurry (Ni-NTA, 250 pi) was added to the recovered supernatant and incubated with gentle mixing 
for 2 hour at 4°C. The mixture was applied to a minicolumn for gravity flow chromatography. The resin 
was washed with 50 ml each o f 15, 20, mM imidazole and 20 ml o f 30, 40, 50, 75 mM imidazole wash 
buffer (50 mM NaH2 PO, pH 8.0; 300 mM NaCl). The synthetase was eluted with elution buffer (50 mM 
NaH2PO, pH 8.0; 300 mM NaCl; 250 mM imidazole). The presence o f synthetase in the elution fractions 
was determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE; 7.5.1) and 
fractions containing the synthetase were pooled and concentrated by centrifugation in AMICON tube 
(Millipore). The protein was further purified by FPLC size-exclusion column (7.5.2).
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7.5.1 SDS-PAGE
SDS-PAGE was used as a protein detection method. Normally, 15 pi protein samples were mixed with 
5* Sample buffer (see below) and denaturated in 80°C/10 min. Next, samples were run on 
polyacrylamide gel (Acrylamide solution, SIGMA-ALDRICH) composed of 13 % Separating and 4 % 
Stocking gel (see below), at 150 -  200 V for 60-90 minutes. Protein ladder (10-250 kDa, NEW  
ENGLAND BioLabs) was run together with samples, in order to determine molecular weight of the 
sample bands. After the run, gel was stained in Coomassie Brilliant Blue staining buffer (see below) 
and distained in water. Gels were visualized (VersaDoc™ Imaging System, BIO RAD).
5* Sample buffer
Tris-HCl pH 6 . 8
2 -mercaptoethanol
SDS
Glycerol
Bromophenol blue
0.2 M 
10 mM 
1 0 % 
2 0 % 
0.05 %
10* Catode buffer
Tris-HCl pH 8.25 1 M
Tricine 1 M
SDS 1 %
10x Anode buffer
Tris-HCl pH 8.9 2.1 M
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Separating gel (4 short gels)
40 % Acrylamide solution 1 0  ml
Gel buffer* 1 0  ml
70 % Glycerol 4 ml
h2o 6 . 2  ml
10 % APS 133 |xl
TEMED 13,2 nl
Stocking gel (4 short gels)
40 % Acrylamide solution 2 . 1 2  ml
Gel buffer* 5 ml
h2o 13.44 ml
10 % APS 160 pi
TEMED 16 pi
*Gel buffer
Tris-HCl pH 8.45 3 M
SDS 0.3 %
Coomassie Brilliant Blue staining buffer
Ethanol 250 ml
Acetic acid 80 ml
Coomassie Brilliant Blue R-250 2.5 g
H20 Up to 1 litre
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7.5.2 Analytical gel filtration
In order to obtain maximum protein purity, we used Superdex 200 100/300 GL or Superdex 75 10/300 
GL size-exclusion columns. The purification was usually run with the flow rate of 0.4 ml/min, on 
AKTApurifier UPC (GE Healthcare) in buffer A: 50 mM Tris-HCl pH 8.5, 150 mM NaCl, 5 mM P- 
mercaptoethanol and 0.5 mM EDTA. Before actual experiments, purity o f the protein was determined by 
SDS-PAGE. To analyze molecular weight of the protein samples for ITC, buffer I (50 mM Tris (pH 8), 
300 mM NaCl, 2% glycerol, 0.5 mM EDTA) was used.
7.6 Protein concentrations
Protein concentrations for Bs TrpRSs (molecular mass: Bs TrpRS Val144Pro = 40,978 Da, wt Bs TrpRS = 
40,980 Da and Bs TrpRS Val144Pro + tag = 43,833.4 Da) were determined from their extinction 
coefficient at 280 nm ( 8 2 8 0  = 27,975 M^.cm'1, 8 2 8 0  = 27,975 M^.cm'1 and S2 8 0  = 33,475 M^.cm"1) and 
confirmed by nanodrop (Labtech International Ltd.) and Bradford protein assay (BIO RAD) with bovine 
serum albumin (BSA) as a standard. The extinction coefficient was calculated from protein sequence 
(ProtParam tool).
7.7 Complementation of E. coli KY4040
Competent E. coli KY4040 (6.3) were co-transformed with pGPl-2 (KanR) (6.1), which encodes T7 
RNA polymerase, and with pET plasmids encoding either wt or mutant Bs TrpRS (AmpR) (6.2). As a 
control, we also transformed E. coli KY4040 with an empty pET151e vector. Cells were plated, 
cultivated overnight at 37°C on M9 minimal media (6.7) plates containing 50 pg/ml ampicilin, 25 pg/ml 
kanamycin and 0.5 mM L-trp. Prior to the complementation experiment, four single colonies were 
selected from each of the plates and resuspended in a separate 20 pi volume of deionizediialgr. In order
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to obtain a similar density o f the E. coli KY4040 cells containing three different constructs, we measured 
the cell absorbance (600 nm) on the nanodrop (Labtech International Ltd.). M9 minimal media plates 
containing either 0.05 pM L-trp or 5 pM 5-OH Trp were inoculated by the same amount of the E. coli 
KY4040 containing pGPl-2 and either of three different pET151 (pET151 wt Bs TrpRS, pET151 Bs 
TrpRS Val144Pro or pET151e). This inoculation was done in three separate sections on the plate.
7.8 Isothermal titration calorimetry
Calorimetric measurements were carried out using a VP-isothermal titration calorimeter (MicroCal) at 
25°C. Prior to titration, concentrated Bs TrpRS’s protein samples were dialyzed overnight against buffer 
I: 50 mM Tris (pH 8), 300 mM NaCl, 2% glycerol, 0.5 mM EDTA. The final dialysate was used to 
prepare ligand solutions.
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Results and Discussion
Because of the complexicity of the mammalian system, we have not repeated techniques that the 
original report used. Instead, we employed standard methods for the AARS evaluation. These are 
crystallization, complementation assay and ITC. In this manner, we have examined the Vall44Pro Bs 
TrpRS for use in the orthogonal system.
Experimental part of this project was done at Cardiff University Physical Organic Chemistry (POC) 
Centre. Crystallization data were collected at the Diamond Light Source in the UK, by Sam Hart from 
York Structural Biology Lab. Crystallization and structure refinement were carried out with help of Prof. 
Matthias Bochtler, Dr Honorata Czapinska and Dr Ania Piasecka. ITC experiments were performed with 
help of Dr Niklaas J. Buurma and Dr Lavinia One 11.
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8. Mutagenesis, expression and purification
In order to confirm a single Pro144Val mutation in Bs TrpRS (6.2), I isolated a number of plasmid 
samples (GS43463 pBSK/Rs TrpRS) from bacterial cultures (6.9). After sequencing, one of the samples 
showed the GTC (Val144) mutation in the desired place (Figure 20).
^  Ttm jlm c*____________________
• V  Top
► B o tto m
o p t i m i s e d  s e q u e n c e _ V a l l4 4 P t o .S E Q ( 1 > 1 0 0 2 ) —>
▼  1 8 0 8 0 e _ 6 5 i3 4 _ T r p R S v m l3 _ H 1 3 r .  a b l  (1 > 1 1 2 2 )  — *
► l8 0 8 0 8 _ 6 S 1 3 S _ T r p R S v m l3 J B 1 3 R .a b l ( l> 1 1 8 1 )  <—
Figure 20: Sequencing chromatogram (SeqMan). Sequences show the place of Pro144Val (GTC) 
mutation in both M13F and M13R samples. These are aligned with the original Bs TrpRS Val144Pro (CCC) 
sequence.
I verified the cloning reaction of wt Bs TrpRS or Bs TrpRS Vall44Pro into pET151/D-TOPO by 
colony PCR, agarose gel electrophoresis and sequencing (7.1, 7.2.1, 7.3). The positive clones that 
contained the insert could be distinguished on the electrophoresis gel as they were bigger than the 
negative clones (empty pET151e). Sequencing also showed the right position of Bs TrpRS’s in 
pET151/D-TOPO vector.
In order to obtain high protein yields, I overexpressed wt Bs TrpRS, Bs TrpRS Val144Pro, Bs TrpRS
Val144Pro + tag in pET151/D-TOPO with optimized conditions and temperature (7.4). When Ni-NTA
purification was applied, part of the protein started to elute in the wash buffer containing 20 mM
imidazol but this fraction displayed high impurity. The rest of the protein eluted in 30, 40, 50, 75, 250
mM imidazol fractions with similar purities (Figure 21). Therefore, when repeating Ni-NTA purification,
after 30 mM imidazol wash, I eluted protein directly in 250 mM imidazol buffer. This was in order to
obtain highly concentrated samples for ITC and crystallization. For the size exclusion on Superdex 75
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100/300 GL (Amersham Biosciences), I combined fractions 30 mM (40 mM, 50 mM, 75 mM if used) 
and 250 mM imidazol. In the size exclusion purification, the greatest part of the target protein was 
typically found in fractions 10, 11, 12 and 13 (Figure 22). After protein chromatography, SDS-PAGE 
confirmed sufficient purity of the concentrated protein samples for crystallization and ITC (Figure 23). 
For protein crystallography, I used the purest fractions 11 and 12 for further dialysis and concentration 
whereas for ITC, I typically combined and dialyzed fractions 10, 11, 12 and 13.
1 2 3 4  5 6 7 8 9 10 11 12
Figure 21: SDS protein gel analysis of Bs TrpRS expression at different 
steps of Ni-NTA purification. Electrophoresis was run on a 13% SDS gel 
and stained by Coomassie blue. 1 -  prestained protein marker {BioLabs) with 
molecular weights of 175, 80, 58, 46, 30, 23, 17 and 7 kDa, respectively, 2 - 
flow through fraction, 3 - first wash fraction with 15 mM imidazol, 4 - wash 
fraction with 20 mM imidazol, 5 - wash fraction with 30 mM imidazol, 6 - 
wash fraction with 40 mM imidazol, 7 - wash fraction with 50 mM imidazol, 
8 - wash fraction with 75 mM imidazol, 9 - eluted fraction with 250 mM 
imidazol, 10 - control TrpRS, 11 - control Hcpl protein ~ 20 kDa, 12 - 
control TrpRS.
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Figure 22: Size exclusion purification of Bs TrpRS on Superdex 75 10/300 GL (Amersham Biosciences). The
purification was performed on AKTApurifier UPC (GE Healthcare), with 0.4 ml/min flow rate and 1.8 MPa 
maximum column pressure, in a room temperature (in buffer A: 50 mM Tris-HCl pH 8.5, 150 mM NaCl, 5mM |3- 
mercaptoethanol and 0.5 mM EDTA). The elution profile was monitored at 280 nm. Protein was typically found in 
fractions 10, 11, 12 and 13.
40kDa
Figure 23: SDS protein gel analysis of Bs TrpRS 
after size-exclusion protein chromatography.
Electrophoresis was run on a 13% SDS gel and 
stained by Coomassie blue. 1 -  prestained protein 
marker (BioLabs) with molecular weights of 175, 
80, 58, 46, 30, 23, 17 and 7 kDa, respectively, 2 -  
8 fraction, 3 - 9  fraction, 4 - 1 0  fraction, 5 - 1 1  
fraction, 6 - 1 2  fraction, 7 —13 fraction.
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9. Analytical gel filtration
In order to determine Molecular weights o f wt Bs TrpRS and Bs TrpRS Val144Pro protein samples 
experimentally, I calibrated Superdex 200 100/300 GL (Amersham Biosciences) in buffer I (7.8) with a 
gel filtration protein standard (BIO RAD). This standard contained: protein aggregates, thyroglobulin 
(670 kDa), bovine y-globulin (158 kDa), chicken ovalbumin (44 kDa), equine myoglobin (17 kDa), 
vitamin B12 (1.35 kDa) and tryptophan (204.23 Da) (Figure 24. A). From the protein standard elution 
profile at 280 nm, a linear dependence of the logarithm of the molecular mass on the elution time was 
calculated (Figure 24. D). I analyzed molecular weight of wt Bs TrpRS and Bs TrpRS Val144Pro by using 
the same buffer I (as for calibration). Wt Bs TrpRS eluted from the column at 12.76 ml (this was taken as 
an average of 3 runs), responds to the molecular weight of 76,19 kDa and Bs TrpRS Val144Pro at 12,715 
ml (this was taken as an average of 3 runs), responds to 78 kDa (Figure 24. B, C). Molecular weights of 
analyzed synthetases suggested that both wt Bs TrpRS and Bs TrpRS Val144Pro form a dimer in buffer I 
(for the ITC experiment).
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Figure 24: Analytical gel filtration on Superdex 200 10/300 GL (Amersham Biosciences). This experiment 
indicated that wt Bs TrpRS and Bs TrpRS Val144Pro form a dimer. The gel filtration was performed on AKTApurifier 
UPC (GE Healthcare), with 0.4 ml/min flow rate and 1.5 MPa maximum column pressure, in a room temperature (in 
buffer I: 50 mM Tris (pH 8), 300 mM NaCl, 2% glycerol, 0.5 mM EDTA). The elution profile was recorded at 280 nm. 
A -  gel filtration standard {BIO RAD) elution profile that indicates that; protein aggregates eluted from the column at 
7.62 ml, thyroglobulin at 8.25 ml, bovine y-globulin at 11.34 ml, chicken ovalbumin at 14.24 ml, equine myoglobin at 
16.21 ml and vitamin B12 at 19.81. B - wt Bs TrpRS that eluted at 12.77 ml. C -  Bs TrpRS Val144Pro that eluted at 
12.71 ml. D -  calibration curve with gel filtation standard {BIO RAD). E - Molecular weight - MW [kDa], logarithm of 
the molecular weight -  Log (MW) and the elution time -  V [ml] values for the BIO RAD standard, wt Bs TrpRS and Bs 
TrpRS Val144Pro. Wt Bs TrpRS and Bs TrpRS Val144Pro MW values were calculated from the linear function of the 
logarithm of the standard molecular weight on the elution time. Wt Bs TrpRS responds to MW -  76.19 kDa and Bs 
TrpRS Val144Pro to MW = 78 kDa. These values are also indicated in bold.
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Calibration curve
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0
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V [ml]
♦  8.25 ♦  11.34 ♦ 1 2 .7 1 5  ♦  12.76 ♦  14.24 ♦  16.21 ♦ 1 9 .8 1
E.
Protein MW [kDa] Log (MW) V [ml]
Protein Aggregates 7.62
Thyroglobulin 670 2.826075 8.25
Bovine y- Globulin 158 2.198657 11.34
Chicken ovalbumin 1.643453 14.24
Equine myoglobin 1.230449 16.21
Vit B12 1.35 0.130334 19.81
Tryptophan 0.204
wt Bs TrpRS 76,19 1.881873 12.76
Bs TrpRS Val144Pro 1.89214 12.715
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10. Crystal structure of Bs TrpRS Val144Pro
10.1 Crystallization and data collection
I crystallized the Bs TrpRS Val144Pro + tag mixed with equal concentrations of L-Trp and 5-OH 
Trp. (EC 6.1.1.2) at temperature 16°C by the vapour diffusion technique. A Cartesian robot was used to 
pre-screen crystallization conditions and identified two promising lead conditions. Both o f them could be 
scaled up to larger volume. The largest and best-looking crystals were grown by mixing 9 mg/ml protein 
in buffer C: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM 2-Mercaptoethanol, 0.5 mM EDTA, 0.5 
mM L-Trp, 0.5 mM 5-OH Trp, with an equal volume of buffer 0.1 M MES (pH 6.5), 12% PEG 20 000 
and equilibrated against this buffer in the reservoir solution. Smaller and less regular crystals could also 
be obtained by using the same buffer C, mixing with a half volume of buffer 25% PEG 1500, 66.4 mM 
SPG* (pH 10), 33.6 mM SPG* (pH 4) in a crystallization drop and equilibrated against this buffer in the 
reservoir (SPG* = 1 M succinic acid, 1 M NaH2 P0 4 H2 0 , 1 M glycine). The larger and nicer crystals 
turned out to be very difficult to protect for flash cryo-cooling. Eventually, with help of Prof. Matthias 
Bochtler we found a buffer that allowed us to record and index a diffraction pattern on a synchrotron 
beamline, but the pattern was nevertheless clearly marred by the problems in the cryo-protection step. 
The smaller and less attractive crystals could be cryo-protected straightforwardly (0.05 M MgCl2.6H20 , 
0.05 M HEPES sodium pH 7, 25% PEG 550, 14% glycerol), but diffracted only to lower resolution. 
Although the two groups of crystals were not superficially similar in morphology, a comparison o f the 
indexing results suggested that all crystals belonged to the same crystal form. Therefore, the cryo-buffer 
for the crystals of less attractive morphology was tested for the larger crystals and turned out to work. 
Data was collected by Sam Hart, integrated and scaled by Prof. Matthias Bochtler with XDS and 
SCALA (CCP4-6.1.3).
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10.2 Crystal structure determination by molecular replacement
Bs TrpRS Val144Pro + tag crystals were orthorhombic and with the synchrotron radiation diffracted 
to 2.8 A. Indexing, done by Prof Matthias Bochtler, yielded a unit cell with dimension 49.2 x 119.8 x
127.3 A. Based on solvent content; crystals were expected to contain two protomers in the asymmetric 
unit. Due to non-measured data on the reciprocal coordinate axis, which was later assigned as OkO, the 
pattern of systematically absent reflections on this axis was unknown and thus the space group remained 
ambiguous ( P2(l)2( 1)2(1) or P2( 1)22(1) equivalent to P2(l)2(l)2 in the standard nomenclature). The 
number of reflections measured for the axis later assigned as 001 was also quite limited. Due to the 
uncertainty about the two 2-fold axes, translation searches were separately carried out for all 
orthorhombic space groups. For molecular replacement searches (Prof Matthias Bochtler), we used the 
MOLREP program. As a search model, we used a monomer of the TrpRS from B. stearothermophilus 
(PDB ID 3FIO),207 which is 76% identical in sequence to the B. subtilis homologue, but did not obtain 
clear-cut results. Assuming the conservation o f the dimer interface, we next tried to position the frill B. 
stearothermophilus dimer in the unit cell. The rotation search now yielded two rotational solutions 
(corresponding to the two ways to superimpose homologous dimers) that stood out from the noise. For 
these rotational solutions, the translation function scores and R-factors stood out from the noise for space 
group P2(l)2(l)2(l), but not for other screw axes assignments. Inspection of the molecular replacement 
solution showed satisfactory molecular packing in all three dimensions of the crystal.
10.3 Refinement
In spite of the very significant sequence similarity between the template and the target structure, the 
initial R-factor for the molecular replacement solution was rather high, indicating that movements and 
other local changes needed to be corrected manually (done by me under supervision of Dr Honorata
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Czapinska). This was done with the modeling program COOT. Cycles of model improvement were 
alternated with refinement cycles using the REFMAC maximum likelihood refinement program. The 
Ramachandran plot statistics showed quality o f the structure refinement. 91.9 % of the peptide dihedral 
angles are in the most favoured regions, 7.7 % in the additionally allowed regions, 0.4 % in the 
generously allowed region and 0 % in the disallowed region. Due to the limited resolution of the 
diffraction data, no attempt was made to build water molecules in the structure. We also did not attempt 
to use global anisotropic temperature factors (TLS) because refinement appeared satisfactory also in the 
absence of these assumptions. Crystal model evaluation was done with PROCHECK and MolProbity.
The crystal structure, atomic coordinates and structure factors have been deposited as; tryptophan- 
tRNA synthetase Vall44Pro mutant from B. subtillis, in Protein Data Bank (PDB ID 3PRH).204 The 
statistics for the best dataset, collected at the Diamond Light Source in the UK, are presented in Table 
14.
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Table 14: Data collection and refinement statistics
Data collection statistics
Space group P2(l)2(1)2(1)
a (A) 49.258
b (A) 119.816
c(A) 127.353
Resolution range (A) 30.0-2.8
Total reflections 137536
Unique reflections 19307
Completeness (%) (last shell) 99.9 (100.0)
I/o (last shell) 13.5 (2.6)
R(sym) (%) (last shell) 5.0 (30.0)
B(iso) from Wilson (A2) 71.8
Refinement statistics
Protein atoms excluding H 4958
Solvent molecules 0
R-factor (%) 23.52
R-free (%) 27.50
Rmsd bond lengths (A) 0.012
Rmsd angles (°) 1.3
Ramachandran core region (%) 91.9
Ramachandran allowed region (%) 7.7
Ramachandran additionally allowed region (%) 0.4
Ramachandran disallowed region (%) 0.0
10.4 Overall structure
Bs TrpRS (Figure 25) is a typical homodimeric a2 enzyme. As in the case of the Carter’s Bst TrpRS 
(PDB ID 3FIO),207 each monomer of Bs TrpRS contains two unequal domains. The bigger domain 
(residues 1-200) has a Rossmann fold (RF) built of 4 — stranded parallel 6-strands linked with a-helical
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crossover connections. In this region, we noticed the characteristic TIGH and KMSKS consensus 
sequences (in the N- and C-terminal parts of RF, respectively). The small domain (SD; residues 207-280) 
consists of 4 high motion helices with one of them stretching through the whole length of a monomer 
(residues 265-326) and terminating at the dimer axis.
Figure 25: Bs TrpRS Val144Pro homodimer crystal structure 
model. Two homologue monomers are distinguished as blue and 
green. Each monomer has its bigger domain, the Rossmann 
dinucleotide-binding region comprising a Rossmann fold (RF) and a 
small domain (SD). Two important consensus sequences are TIGH 
(orange) and KMSKS (yellow); and regions with a great mobility are 
in black. A long helix (pink or light pink) expands from the SD onto 
the dimer interface.
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10.5 Active site
Because the crystal of the Bs TrpRS Val144Pro mutant diffracted to only 2.8 A, we could not find 
electron density for either L-Trp or 5-OH-L-Trp in the synthetase active site (Figure 26). However, we 
superimposed the structures of Bs TrpRS Val144Pro and Bst TrpRS (PDB ID 3FIO)207 and found the 
expected ligand binding position (Figure 27).
Proi45
Proi44
Figure 26: Bs TrpRS Val,44Pro active site electron density map.
Positions of Asp133, Pro144, Pro145 and Val146 are indicated. This is the 
site where a ligand would be expected to bind.
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Figure 27: Stereoview of Bs TrpRS Val144Pro Rossmann fold binding site 
(green) with a modeled L-Trp from Bst TrpRS structure. TIGH and KMSKS 
are coloured in orange and yellow; and the long extended helix in pink.
After the superposition of the two synthetase structures (Bs TrpRS Val144Pro and Bst TrpRS - PDB 
ID 3FI0207), we were able to have a closer look at any differences in the position of active site elements. 
In particular, we were curious whether the position of Asp133 (equivalent of Asp132 in Bst TrpRS), the 
main L-Trp determinant, was altered due to the Val144Pro mutation. However, we did not detect any 
significant differences in the conformation of this residue (Figure 28). Despite the fact that residue 144 is 
only about 6 A from 5-position of L-Trp, the Val144Pro mutation does not have a considerable effect on 
the synthetase secondary structure. However, we were able to detect a loop disposition in place of 
Val144Pro mutation.
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Vali44Pro
Aspm
Figure 28: Bs TrpRS Val144P roand  Bst TrpRS (brown) structures alignment. L-trp (cyan blue), AMP 
(dark blue) and inorganic phosphate (orange) comes from Bst TrpRS structure and no ligand was present in 
Bs TrpRS Val144Pro structure. RF comprises Val144Pro mutation (green) from Bs TrpRS Val144Pro and 
Val143 (brown) from Bst TrpRS that are magnified in an extra window. In this area, we also see the loop 
disposition caused by the mutation. Asp133 residue has not changed its position and is identical to Asp132 in 
Bst TrpRS.
From our analysis of the unmodified Asp133 in Bs TrpRS Val144Pro active site, it appears that this 
gatekeeper residue in an aminoacylation reaction would recognize L-Trp and it is unlikely that the 
synthetase mutant would switch its specificity to only 5-OH Trp. This does not correspond to what 
Schultz has described.76 In terms of the Val144Pro mutation, previous work207 suggested that this 
mutation gives rise to some conformational changes in the place where Asp146 binds the ribose of ATP. 
This could have an effect on the catalytic efficiency of the synthetase. In order to investigate how 
Val144Pro mutation does influence the amino acylation, I carried on with the complementation assay.
112
Results and Discussion
11. Complementation assay results
I used E. coli KY4040 strain (6.3)208,209 to test the activity of exogenous Bs TrpRS’s. This 
auxotrophic strain displays a mutation in the trpS structural gene and therefore TrpRS is unstable. 
Growth of the strain could be stabilized by access of tryptophan in the presence of ATP and the 
growth rate depends on the concentration o f tryptophan.208 In order to complement the auxotrophic 
phenotype under Trp-starved conditions, I co-transformed E. coli KY4040 with pGPl-2 and one of 
three pET151 plasmids (i.e. pET151 wt Bs TrpRS, pET151 Bs TrpRS Val144Pro or pET151e) (6.1, 
6.2). In order to facilitate T7 polymerase expression in pGPl-2 (6.1), under the temperature sensitive 
cI857 repressor, I grew cells at 37°C. Only in presence of wt Bs TrpRS, KY4040 cultures were 
complemented and grew after 48 h, either in presence of 0.05 pM L-Trp or 5 pM 5-OH Trp (Figure 
29). This result confirmed that 5-OH Trp is substrate for wt Bs TrpRS as oppose to the original 
report.76 There was no growth detected in presence of Bs TrpRS Val144Pro and L-Trp or 5-OH Trp, 
which was identical with the control experiment (where no synthetase was expressed) (Figure 29). 
This result showed that Bs TrpRS Val144Pro has no ability to charge a tRNATrp with either L-Trp or 5- 
OH Trp.
All experiments were repeated 3 times.
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Figure 29: E. coli KY4040 complementation assay in presence of 0.05 pM L-Trp (left) and 5 pM  5-OH 
Trp (right). Cell cultures were grown in three sections on M9 minimal media (6.7) plates containing 50 pg/ml 
ampicilin, 25 pg/ml kanamycin, at 37°C/48 h. 1 - pET151 wt Bs TrpRS /pGPl-2, 2 - pET151 TrpRS 
Val144Pro/ pGPl-2, 3 - PETl51e (control)/pGPl-2.
A complementation assay was used by Soil et al.69 in order to evaluate in vivo activities of wt 
and mutant Bst TrpRS enzymes. Growth of different transformants was compared after 1, 2 and 4 
days. Similarly to our Bs TrpRS Val144Pro, Bst TrpRS Val141Gln mutant was also not able to 
complement KY4040 phenotype after 4 days while wt Bst TrpRS grew after 1 day. As was already 
mentioned in chapter 4.4, the catalytic efficiency of the Bst TrpRS Val141Gln mutant was reduced 
-300 fold for L-Trp and -1000 fold for ATP. Previously studied conformational changes of Asp146, 
binding the ribose of ATP,207 in the Val144Pro mutant suggested the explanation for this catalytic 
efficiency reduction. Our results only confirmed what was already proposed. The Val144Pro mutation 
in Bs TrpRS perhaps affects the ATP ribose binding and therefore lowers the catalytic efficiency of 
the synthetase. Charging o f tRNA with either L-Trp or 5-OH Trp is disturbed and therefore Bs TrpRS 
Val144Pro is not able to complement the auxotrophic phenotype. Thus our results are in disagreement 
with the original report 6. They reported 20% - 40 % translation efficiency and 97% translation
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fidelity of 5-OH Trp incorporation by Bs TrpRS Val144Pro and, thus, should have successfully 
complemented the phenotype of this strain in the presence of 5-OH Trp.
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12. Isothermal titration calorimetry (ITC) for wt Bs TrpRS and Bs TrpRS 
Val144Pro analysis
In order to examine the affinity o f Bs TrpRS wt and Bs TrpRS Val144Pro towards L-Trp and 5- 
OH Trp, I applied ITC.
ITC is a powerful and adaptable technology that measures heat (q) of a binding interaction in
solution.210 ITC directly determines association constant (Ka), enthalpy changes {AH) and binding
stoichiometry (n). From those, one can calculate dissociation constant (KJ), Gibbs free energy change
(AG), and entropy change (AS) of a reaction. Moreover, ITC can also measure catalytic reactions,
conformational rearrangements and changes in protonation. Defining of a full binding curve depends
on ligand solubility and magnitude of binding affinity74. ITC is applicable in biomolecular science,
210drug development and materials engineering. Focus of this work is on a protein - synthetase 
interaction with a ligand - amino acid.
ITC works on a simple principle.210 Figure 30 shows a design of the typical ITC instrument. 
There are two identical cells, held in temperature equilibrium. A sample cell is a place where the 
macromolecule is applied, whereas a reference cell always contains water or buffer. The sample cell 
is temperature controlled. A thermopile/thermocouple circuit connects two cells. Throughout the 
experiment, an instrumental syringe injects a ligand solution into the sample cell, at a fixed 
temperature in the range 5-60 °C.74 The q o f this reaction is either released or taken up (exo- or endo- 
thermic process). This thermal difference is detected by semi-conductor thermopiles. Subsequently, 
the instrument releases a thermal power (pcal/s), in order to compensate for the heat change. This 
brings the cells back into the temperature equilibrium.
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Reference cell Sample cell
Figure 30: Typical ITC instrument set up. The sample cell and the reference cell are kept 
in the temperature equilibrium. The sample cell contains a macromolecule solution into 
which a ligand solution is being injected from the syringe. Whilst the experiment runs and 
single injections are applied, syringe stirs in the sample cell.
ITC measures amount of the reaction heat for every injection with sensitivity to several hundred 
nanojoules. AH  is directly calculated by integrating the thermal power versus time.210 A typical 
experiment is projected as a number of peaks, one peak for every injection. Furthermore, the 
integration of each peak (and correction to a per mole basis) defines specific points of a binding 
curve. Identifying o f a binding curve enables to determine degree of complex formation. In this 
manner, Ka can be calculated and Kd derived from the equation; Ka (KJ1). Moreover, from these 
values, one can calculate (AG) and (AS) as follows:
AG = -RT]nKa; AG = AH -  TAS
Besides, one can run the experiment in different temperatures and determine the heat capacity of 
binding (A Cp):
ACP= d(AH) / dT
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ITC technology has developed largely so that a wide profile of an enzyme binding reaction can 
be obtained.211'213 Despite of this, ITC for enzyme binding kinetics analyzes has not been opened up 
much yet. However, in this project, the main interest was to determine Kd for wt Bs TrpRS and Bs 
TrpRS Val144Pro mutant in reactions with either L-Trp or 5-OH Trp.
ITC have been used in several cases to determine activities of number of synthetases. The 
importance of two tryptophan residues was determined by ITC on human T2-TrpRS and its 
multifunctionality was proven by this method.75 T2-TrpRS binds L-Trp with Kd of 11 pM. Activities 
of different T2-TrpRS mutants towards L-Trp were shown to be reduced or not measurable. In this 
way, crucial residues for the synthetase activity were found. By using the same human T2-TrpRS and 
ITC method, activity towards L-Trp and ATP was measured and compared to the full-length 
TrpRS.214 It was found that T2-TrpRS and TrpRS have comparable affinities for L-Trp (11.3 pM and 
6.8 pM) but not similar for ATP. TrpRS binds ATP with Kd of 20 pM but T2-TrpRS > 0.5 mM. 
Furthermore, ITC was applied to examine the effect of Mg2+ presence on ATP titration with TrpRS 
from Bacillus stearothermophilus.
When designing the ITC experiment, several requirements needed to be considered.210 Firstly, it 
is the sample volume. Except for low volume designed calorimeters, ITC requires a large volume of 
sample. In our experiments I used VP-isothermal titration calorimeter (MicroCal), with ~ 1,4 ml 
sample cell volume. For an easy manipulation, one experiment requires ~ 3 ml of a protein sample. 
Secondly, because ITC measures overall reaction heat, additional heat that does not belong to the 
reaction itself needs to be subtracted. For example, this additional heat could be coming from 
protonation or salvation conformational transition. Therefore, additional dilution experiments are 
required to be run before the actual experiment and subtracted. In our case, such dilution experiments 
were; buffer into buffer, ligand solution into buffer and buffer into the synthetase solution, but they 
did not result in significant heat release. For this reason, I did not deduct this dilution heat of the 
additional experiments but the heat from the last injection of the actual experiment was subtracted
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from every injection instead. In the third place, we need to consider that not every reaction results in a 
large signal to noise. This can be resolved by changing the reaction temperature, as AH  is generally 
temperature-dependence. In our experiments with synthetases from Bacillus subtilis, the temperature 
test is limited to only physiological temperatures, between 25-35 °C. However, I tried two different 
temperatures, 25°C and 30°C, but the difference was trivial for the objective of our study. Because of 
some precipitation formations in our reaction mixtures during the ITC runs, I sticked to only a 
“friendlier” 25 °C temperature. On the other hand, increased concentration of the macromolecule does 
enhance the reaction heat and therefore signal to noise, in our experiments. For this reason, the 
synthetase concentration I used ranges between 81 pM- 181 pM. Finally, ITC can measure Kd value 
in range between ~ InM < Kd < ~ several hundred pM. If Kd o f a macro molecule is too low (tight 
binding) and the concentration is too high, the most of the binding sites saturate in the first injection. 
In this case, only one-step reaction is achieved and the binding curve cannot be analyzed. This can be 
resolved by the macromolecule sample dilution but only until the point that ITC can still detect the 
signal-noise difference. In contrast, it is also challenging to measure very high Kd o f a macromolecule 
(weak interaction)216 binding to a ligand, because of both concentrations (macromolecule and ligand) 
need to reach binding saturation. Yet again, this can be resolved by concentrating of the 
macromolecule sample but only until the sample is still soluble.
In our study, Bs TrpRS is relatively a poor binder when compared to Ec TyrRS (results not
217shown). Limitations of studying poor binding complexes by ITC have been well explored. In order 
to proceed with ITC experimental data, a nonlinear least squares curve fitting needs to be applied that 
faithfully describe the binding event. Since the 1980s,218 when highly sensitive microcalorimeters 
came onto the market, applying the so-called Wiseman isotherm219 for the fitting process has become 
common. This was after Wiseman et al. pointed out that the shape of such binding isotherm changes 
depending on Ka and the concentration of macro molecule ([M]t) that defines a so-called c value. The c 
value can be also taken as the ratio of [M]t and Kd.
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Working with systems where the c value is between 10 -  500 is highly preferable.219,220 Binding
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isotherm is sigmoidal if c > 10 (Figure 31). Therefore, the entire binding curve can be fitted and the 
final points are almost in a vertical order due to a full saturation. It is more difficult to fit a binding 
curve, if c < 10, due to the curve incompleteness and a challenge to achieve a full macromolecule 
saturation (Figure 31).217
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Figure 31: Wiseman isotherms projected by Turnbull et al.217 that 
change their shape as the c value changes. C value is defined by Ka and 
[Mt]. When c < 10, the binding curve loses its sigmoidal shape.
For the low affinity systems, c value is in a range between 0.01 -  10.217 When dealing with these 
systems (Ka < 10 000 M '1; Kd > 100 pM), solubility usually becomes a significant issue. This is 
because higher concentrations of macromolecule and ligand ([M]t »  Kd) is required in order to 
satisfy the c value rule. Even if [M]t «  Kd and we cannot improve the [M]t, the final concentration of 
ligand has to be several times higher than Kd. Nevertheless, it was shown that it is possible to 
determine Ka and therefore AG° for the low affinity systems, with four following conditions.217 (1) 
Significant amount of the binding isotherm is required to use for fitting. (2) Stoichiometry of a
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reaction is required to be known. (3) Concentrations of both macromolecule and ligand are well 
determined. (4) ITC experiment needs to result a sufficient signal to noise difference.
In our experiments, I used the nanodrop and Bradford assay to determine the macromolecule 
concentration. Yet, for the low affinity systems when repeating the same experiment using the same 
concentrations of the macromolecule and ligand, the value of AH° fluctuates. This can be due to the 
error in the concentration measurements. An earlier suggestion217 was to fix the n value in fitting and 
then the differences in AH° may go unnoticed. However, despite the AH° fluctuations, when I 
repeated our experiments in the same conditions and similar concentrations of the macromolecule and 
ligand, I found a constancy of the Kd value in each experiment. Eventually, this was what we aimed 
for, to compare the value of Kd between the wt and the variant synthetases.
ITC titrations performed in this project typically indicated one binding event. In the first ITC 
experiment, I titrated 5 mM L-Trp into 81 pM wt Bs TrpRS, which resulted in Kd = 149 pM (Figure 
32). Titration of 5 mM 5-OH Trp into 118 pM wt Bs TrpRS, increases Kd approximately 7 folds; Kd = 
1079 pM (Figure 33). This is in accordance to what we have expected, as the wt Bs TrpRS prefers its 
natural substrate L-Trp to 5-OH Trp.184 Besides, wt Bs TrpRS shows that the activity towards 5-OH 
Trp, was as described previously.184,195 On the other hand, Bs TrpRS Val144Prohas reduced activity 
towards L-Trp; Kd > 2000 pM, when 7 mM L-Trp is titrated with 151 pM of the protein (Figure 34). 
The last experiment was the titration o f 7 mM 5-OH Trp into 181 pM Bs TrpRS Val144Pro (Figure 
35). Due to a weak interaction and therefore fitting limitations, I estimated the lowest possible Kd 
value to 2700 pM. Because of the experimental limitations mentioned earlier, I could not use higher 
concentrations of synthetases and ligands mainly because o f a bad solubility and a significant heat of 
dilution experiments. For all ITC enthalpograms, the upper panel represents the raw ITC data whereas 
the lower panel shows integrated heat data for every injection. Heat released (kcaPmol) as a function 
of tryptophan concentration was fitted to a one-site model. ITC data analysis was done by IC-ITC 
program (Dr Niklaas Buurma).74,221
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Figure 32: A; Titration of L-Trp (5 mM) with wt Bs TrpRS (81 pM) at pH 8 (50 mM Tris, 300 mM NaCl, 
2% glycerol, 0.5 mM EDTA) at 25°C. Each peak corresponds to 5 pL of ligand injected into the sample cell. B; 
The heat of dilution when ligand is injected into buffer and C; buffer is injected into wt Bs TrpRS in the same 
conditions as A.
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Figure 33: A; Titration of 5-OH Trp (5 mM) with wt Bs TrpRS (118 pM) at pH 8 (50 mM Tris, 300 mM 
NaCl, 2% glycerol, 0.5 mM EDTA), at 25°C. Each peak corresponds to 10 pL of ligand injected into the 
sample cell. B; The heat of dilution when ligand is injected into buffer and C; buffer is injected into wt Bs TrpRS 
in the same conditions as A.
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Figure 34: A; Titration of L-Trp (7 mM) with Bs TrpRS Val144Pro (151 pM) at pH 8 (50 mM Tris, 300 
mM NaCl, 2% glycerol, 0.5 mM EDTA), at 25°C. Each peak corresponds to 40 pL of ligand injected into the 
sample cell. B; The heat of dilution when ligand is injected into buffer C; buffer is injected into wt Bs TrpRS in 
the same conditions as A.
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Figure 35: A; Titration of 5-OH Trp (7 mM) with Bs TrpRS Val144Pro(181 pM) at pH 8 (50 mM Tris, 300 
mM NaCl, 2% glycerol, 0.5 mM EDTA), at 25°C. Each peak corresponds to 10 pL of ligand injected into the 
sample cell. B; The heat of dilution when ligand is injected into buffer and C; buffer is injected into Bs TrpRS 
Val144Pro in the same conditions as A.
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Different studies done on TrpRS activity enable us to compare with our results. Wong et al. 
reported222 that TrpRS from Bacillus subtilis activates L-Trp as well as the three fluorinated 
analogues, DL-4-fluoro-, DL-5-fluoro-, or DL-6-fluorotryptophan (4F-, 5F-, and 6F-Trp), in the ATP- 
pyrophosphate exchange reaction. Their relative activities follow the same order: L-Trp > 4F-Trp > 
6F-Trp > 5F-Trp (Table 15). On the other hand, this represents the reverse order of relative 
hydrophobicity and its importance in TrpRS specific recognition of these compounds. Km values 
estimated for L-Trp and Trp analogs show that the position of fluoro-substituent is critical for the 
active site binding. Position 5 seems to be the most unfavorable when considering the interaction o f 5- 
F-Trp with Bs TrpRS. From our observations, 5-OH Trp interacting with Bs TrpRS is similarly 
unfavorable.
Table 15: Enzymatic selectivity of Bs TrpRS for tryptophan and the fluoroanalogues in ATP-PPi exchange.222
Substrate Km
L-Trp 164 ± 12
4F-Trp 419 ±34
5F-Trp 2606 ±188
6F-Trp 1621 ±169
76From the ITC data I have collected, the previous report is to be contradicted. Bs TrpRS 
Val144Pro, with Kd > 2000 pM for L-Trp and Kd > 2700 pM for 5-OH Trp, displays low binding 
affinity for both substrates. There is no preference of the mutant synthetase towards 5-OH Trp. 
Moreover, Bs TrpRS Val144Pro binds L-Trp and this interaction is even greater than binding with 5- 
OH Trp. These experiments strongly indicate that 5-OH Trp would not have been incorporated with 
fidelity reported by Schultz under the conditions they describe.
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Without doubt, the revalidation of a scientific work is essential. In this project, we reinvestigated 
the key elements of the Bs TrpRS’s achieved fidelity in the expanded genetic code. This investigation 
was important as its analysis can be used to further introduce new functional groups into proteins by 
providing a guide for designing future synthetases for other NAAs. In consideration of the original 
report,76 we examined the effect of the Val144Pro mutation in Bs TrpRS using standard methods i.e. 
crystallography, complementation assay and ITC and found:
I. The crystal structure of Bs TrpRS Val144Pro shed more light on the ligand recognition site.
1 I T
The position of Asp does not change compared to the homologues residue in the Bst 
TrpRS active site. Therefore, there is no reason to expect a changed fidelity from L-Trp to 
5-OH Trp. The active site loop is slightly displaced near the Val144Pro mutation but this had 
no appreciable effect on the position of Asp133.
II. The mutation of Val144Pro produces catalytically inactive synthetase in the complementation 
assay therefore the synthetase translation efficiency and/or fidelity are severly diminished 
towards 5-OH Trp.
III. Bs TrpRS Val144Pro exhibits limited affinity towards ligands, L-Trp and 5-OH Trp in ITC 
experiment, with an actual preference indicated for L-Trp, which is in direct conflict with 
published data.
The results of our experiments contradict the original report.76 Despite the fact that we did not 
follow the same methods as they did, the aim was to collect evidence using standard biochemical means 
to allow their complex system to be more easily interrogated.
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Our results are clearly relevant for all attempts to expand the genetic code by nonnatural amino acid 
mutagenesis. It is instructive to consider the incredible benefits that society has incurred from using 
standard mutagenesis (i.e. mutagenesis involving 20 common amino acids), and how it has added to the 
understanding of how proteins function, helped our understanding of the active site mechanisms of 
enzymes, and has assisted in the design of novel proteins. Thus, given that the inherent benefit from 
nonnatural amino acid mutagenesis may very well rival standard mutagenesis, our results are important 
from the standpoint that they should considerably hasten a highly desirable NAA incorporation 
technology for a mammalian expression system. It would appear that this was not achieved with Bs 
TrpRS Val144Pro mutant that we examined. Therefore, certain conditions need to be addressed if the 
same approach is to repeated successfully. This includes that one apply what has been already well 
studied and documented for a given AARS, and to follow the standard methodology for demonstrating 
high fidelity NAA incorporation.
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Following are sequences of all three used constructs. CCG or GTC nucleotides encoding Pro144 or Val144 
are indicated bold and underlined. Underlined is also a sequence corresponding to an extra tag of TrpRS 
Pro144 + tag in Sequence III.
Sequence I: Bs TrpRS Val144Pro
ATGAAACAGACCATTTTCAGCGGCATCCAGCCATCCGGCAGCGTCACACTGGGTAATTATA 
TT GGCGCT AT G AAAC AATT CGTT G AGCT GC AGC AT GATT AT A ACTCCT ATTTTTGC ATTGTG 
GAT C AGC ACGCG ATT ACGGT GCC AC AGG AT CGT CT GG AACT GCGT AAAAAC AT CCGG AATC 
T GGC AGC ACT GT ACCT GGC AGT GGGT CT GG ACCC AG AAAAAGCG ACCCT GTTT ATCC AGTC 
AG AGGT ACCGGCCC AT GCCC AAGC AGGTT GGAT GAT GC AAT GT GT GGC AT AC ATT GGT GAG 
CTGGAACGCATGACTCAGTTCAAAGATAAAAGCAAAGGCAACGAAGCAGTCGTATCAGGC 
CT GTT AAC AT AT CCGCCGCT GAT GGCT GCGG AT AT CCT GCT GT ACGGG ACGG AT CT GGT CCC 
GCCGGGT GAAG ACC AG AAAC AAC ACCT GG AATT AACGCGT AAT CT GGCT G AACGCTTT AAC 
AAG AAGT AC A AT GAT ATTTTT ACC ATCCCGG AAGTT AAAATT CCG AAGGTT GGGGCGC GC A 
T CAT G AGTTT AAACG AT CCGTT AAAG AAAAT GT CC AAAT CT G ACCCG AAT C AG AAAGC GT A 
C ATT ACCCT GCT GG ACG AACCT AAAC AACT GGAAAAG AAG AT C AAAT CT GCGGT G ACT G AC 
TCT G AAGGT ATCGT AAAATTT G AC AAAG AAAAT AAGCCT GGCGTT AGT AAT CTGCT G AC G A 
TTT AC AGT AT CTTAGGC AAC ACT ACC AT CG AAG AACT GG AGGCG AAGT AT G AGGGG A AAGG 
CTATGGCGAGTTCAAAGGGGACCTGGCGGAAGTGGTTGTTAACGCTCTGAAACCTATTCAG 
GAT CGTT ATT AT GAGCT GATT GAG AGC GAAG AACT GGAT CGT ATTTT AG AT GAGGGT GCCG 
AACGT GCC AAT CGGACCGCC AAC AAAAT GTT AAAAAAAAT GG AAAACGCC AT GGGTTT AG 
GTCGCAAACGCCGCTAA
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Sequence II: wt Bs TrpRS
AT G AAAC AG ACC ATTTT C AGCGGC AT CC AGCC ATCCGGC AGCGT C AC ACT GGGT A ATT AT A 
TT GGCGCT AT G AA AC AATT CGTT G AGCT GC AGC AT GATT AT AACT CCT ATTTTTGC ATTGTG 
GAT C AGC ACGCG ATT ACGGT GCC AC AGG AT CGTCT GG AACT GCGT AAAAAC ATCCGG AATC 
T GGC AGC ACT GTACCT GGC AGT GGGT CTGGACCC AG AAAA AGCG ACCCTGTTT ATCC AGTC 
AG AGGT ACCGGCCC AT GCCC AAGC AGGTT GGAT GAT GC AATGTGT GGC AT AC ATTGGTG AG 
CTGGAACGCATGACTCAGTTCAAAGATAAAAGCAAAGGCAACGAAGCAGTCGTATCAGGC 
CT GTT AAC AT ATCCGCCGCT GAT GGCT GCGG AT AT CCT GCT GT ACGGG ACGG ATCT GGTCCC 
GGTCGGT GAAG ACC AG AAAC AAC ACCT GGAATT AACGCGT AAT CT GGCT G AACGCTTT AAC 
AAG AAGT AC AAT GAT ATTTTT ACC ATCCCGGAAGTT AAA ATT CCG AAGGTT GGGGCGCGC A 
T CAT G AGTTT AAACG ATCCGTT AAAG AAAAT GT CC AA AT CT G ACCCG AAT C AG AAAGC GT A 
C ATT ACCCT GCT GG ACG AAC CT AAAC AACT GG AAAAG AAG AT C AAAT CT GCGGT G ACT G AC 
T CT G AAGGT AT CGT AAAATTT GAC AAAG AAAAT AAGCCT GGCGTT AGT AAT CT GCT G ACG A 
TTT AC AGT AT CTT AGGC AAC ACT ACC AT CG AAG AACT GG AGGCG A AGT AT G AGGGG A A AGG 
CT AT GGCG AGTT C AAAGGGG ACCT GGCGG AAGT GGTT GTT AACGCT CT G AAACCT ATT C AG 
GAT CGTT ATT AT GAGCT GATT GAG AGCG AAG AACT GGAT CGT ATTTT AG AT G AGGGT GCCG 
AACGT GCC AAT CGGACCGCC AAC AAAAT GTT AAAAAAAAT GG AAAACGCC AT GGGTTT AG 
GTCGCAAACGCCGCTAA
Sequence III: Bs TrpRS Val144Pro + tag
ATGAAACAGACCATTTTCAGCGGCATCCAGCCATCCGGCAGCGTCACACTGGGTAATTATA 
TT GGCGCT AT G AAAC A ATT CGTT GAGCT GC AGC AT GATT AT AACT CCT ATTTTT GC ATT GT G 
GAT C AGC ACGCG ATT ACGGT GC C AC AGG ATCGT CT GG AACT GCGT AAAAAC ATCCGG AAT C
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T GGC AGC ACT GTACCT GGC AGT GGGT CT GGACCC AG AAAAAGCG ACCCTGTTT ATCC AGTC 
AGAGGTACCGGCCC AT GCCC AAGC AGGTTGGAT GATGC AAT GT GT GGC ATAC ATTGGTGAG 
CT GG AACGC AT G ACT C AGTT C AAAG AT AAAAGC AAAGGC A ACG A AGC AGT CGT ATC AGGC 
CT GTT AAC AT ATCCGCCGCT GAT GGCT GCGG AT AT CCT GCT GT ACGGG AC GG ATCTGGTCCC 
GCCGGGT GAAG ACC AG AAAC AAC ACCT GG AATT AACGCGT AAT CT GGCT G AACGCTTT AAC 
AAG AAGT AC A AT GAT ATTTTT ACC ATCCCGG AAGTT AAA ATT CCG AAGGTT GGGGCGC GC A 
T CAT G AGTTT AAACG AT C CGTT AAAG AAAAT GTCC AAAT CT G AC CCG AAT C AG AAAGCGT A 
C ATT ACCCT GCT GG ACG AAC CT AAAC AACT GG AAAAG AAG AT C AAAT CT GCGGT G ACT G AC 
TCT G AAGGT AT CGT A AA ATTT G AC AAAG AAAAT AAGC CT GGCGTT AGT AAT CT GCT G AC G A 
TTT AC AGT ATCTT AGGC AAC ACT ACC AT CG AAG AACT GG AGGCG AAGT AT G AGGGG AAAGG 
CT AT GGCG AGTT C AAAGGGG ACCT GGCGG AAGT GGTT GTT A ACGCT CT G AAACCT ATT C AG 
GAT CGTT ATT AT GAGCT GATT GAG AGCG AAG AACT GGAT CGT ATTTT AG AT G AGGGT GCCG 
AACGT GCC AAT CGGACCGCC AAC AAAAT GTT AAAAAAAAT GG AAAACGCC AT GGGTTT AG 
GTCGCAAACGCCAAGGGCGAGCTCAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGA
GTT GGCT GCT GCC ACCGCT G AGC AAT AACT AG
